08-18-00 A

UTILITY PATENT APPLICATION TRANSMITTAL

Submit an original and a duplicate for fee processing

(Only for new nonprovisional applications under 37 CFR §1.53(b))

ADDRESS TO:

Commissioner of Patents and Trademarks
Box Patent Application
Washington, D.C. 20231

Attorney Docket No. 205970

First Named Inventor Arnd BAUMANN

Express Mail No. EL643535335US

APPLICATION ELEMENTS

1. ☒ Utility Transmittal Form
2. ☒ Specification (including claims and abstract) [Total Pages 47]
3. ☒ Drawings [Total Sheets 18]
4. ☐ Combined Declaration and Power of Attorney [Total Pages]
   a. ☐ Newly executed
   b. ☐ Copy from prior application **[Note Box 5 below]**
      i. ☐ Deletion of Inventor(s) Signed statement attached deleting inventor(s) named in the prior application
5. ☐ Incorporation by Reference: The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Microfiche Computer Program
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
   a. ☐ Computer Readable Copy
   b. ☒ Paper Copy
   c. ☐ Statement verifying above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet and document(s))
9. ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)
    ☐ Form PTO-1449
    ☐ Copies of References
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (Should be specifically itemized)
14. ☐ Small Entity Statement(s)
    ☐ Enclosed
    ☐ Statement filed in prior application; status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
16. ☒ Other: Patent Application Cover Sheet

17. **If a CONTINUING APPLICATION**, check appropriate box and supply the requisite information in (a) and (b) below:
    (a) ☐ Continuation ☐ Divisional ☒ Continuation-in-part of prior application Serial No. PCT/EP99/00942 filed February 12, 1999.
    Prior application information: Examiner ; Group Art Unit:
    (b) Preliminary Amendment: Relate Back - 35 USC §120. The Commissioner is requested to amend the specification by inserting the following sentence before the first line:
    "This is a ☒ continuation-in-part ☐ divisional of copending application(s)
    ☐ Application No. , filed on .
    ☒ International Application No. PCT/EP99/00942, filed on February 12, 1999, and which designates the U.S."

APPLICATION FEES

BASIC FEE				$690.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	46 -20=	26	x $18.00	$468.00
Independent Claims	5 - 3=	2	x $78.00	$156.00
☐ Multiple Dependent Claims(s) if applicable			+$260.00	$
			Total of above calculations =	$1,314.00
			Reduction by 50% for filing by small entity =	$(0.00)
☐ Assignment fee if applicable			+ $40.00	$
			TOTAL =	$1,314.00

UTILITY PATENT APPLICATION TRANSMITTAL | Attorney Docket No. 205970

19. ☒ Please charge my Deposit Account No. 12-1216 in the amount of $1,314.00.

20. ☐ A check in the amount of $ is enclosed.

21. The Commissioner is hereby authorized to credit overpayments or charge any additional fees of the following types to Deposit Account No. 12-1216:
    a. ☒ Fees required under 37 CFR §1.16.
    b. ☒ Fees required under 37 CFR §1.17.

22. ☒ The Commissioner is hereby generally authorized under 37 CFR §1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR §1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 12-1216 for any fee that may be due in connection with such a request for an extension of time.

23. CORRESPONDENCE ADDRESS

☒Customer Number: 23460 **23460** PATENT TRADEMARK OFFICE	☐ , Reg. No. Leydig, Voit & Mayer, Ltd. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Name	Carol Larcher, Registration No. 35,243
Signature	Carol Larcher
Date	August 17, 2000

Certificate of Mailing Under 37 CFR §1.10

I hereby certify that this Utility Patent Application Transmittal and all accompanying documents are being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 CFR §1.10 on the date indicated below and is addressed to: Commissioner of Patents and Trademarks, Box Patent Application, Washington, D.C. 20231.

Irina Mikitiouk	I. Mikitiouk	August 17, 2000
Name of Person Signing	Signature	Date

Attorney Docket No.
205970

PATENT APPLICATION

Invention Title:
SEQUENCES OF AN I_H ION CHANNEL AND USE THEREOF

Inventors:

INVENTOR'S NAME	CITIZENSHIP	CITY OF RESIDENCE	STATE or FOREIGN COUNTRY
Arnd BAUMANN	Germany	Juelich	Germany
Wolfgang BONIGK	Germany	Juelich	Germany
Renate GAUSS	Germany	Juelich	Germany
Alexander SCHOLTEN	Germany	Dormagen	Germany
Reinhard SEIFERT	Germany	Aachen	Germany
Benjamin KAUPP	Germany	Aachen	Germany

Be it known that the inventors listed above have invented a certain new and useful invention with the title shown above of which the following is a specification.

Sequences of an I_h ion channel and use thereof

The present invention relates to a nucleic acid, preferably a DNA, comprising at least part of the sequence of an I_h ion channel. Said sequence may e.g. be derived from a human DNA, a rat DNA, a bovine DNA, a *Drosophila melanogaster* DNA or a sea urchin DNA. Furthermore, the present invention relates to an mRNA molecule which contains the corresponding sequences. The invention further relates to a polypeptide or protein comprising the corresponding derived amino acid sequence.

Furthermore, the invention relates to the use of one or more of the above-mentioned sequences in a screening and/or diagnosing method and to the kits required therefor.

Lastly, the invention relates to the use of one or more of the above-mentioned sequences for the treatment and/or prophylaxis of cardiovascular disorders and sleep disturbances.

The many different functions of the nerve system are substantially determined by finely adjusted interactions between the intrinsic characteristics of the neurons and the synaptic connections. The electrophysiological characteristics inherent to the neurons and synapses are, in turn, determined by the localization and density of the voltage- and ligand-controlled ion channels which regulate the flow of ion currents across the neuronal plasma membrane and which are controlled by a great number of transmitter substances and intracellular messenger systems (Hille, 1992).

With regard to the specific activity expected of the neuronal elements, it is not astonishing that neurons have a great repertory of ion channels, including the classic

channels that produce voltage-dependent sodium (NA^+) and potassium (K^+) currents during an action potential (Hodgkin and Huxley, 1952) and also a number of unusual ion conductances (Linás, 1988).

An unusual intrinsic mechanism which had originally been discovered by Ito and colleagues (Araki et al., 1962; Ito and Oshima, 1965) in motoneurons of cats turned out to be a slow relaxation of the potential change induced by hyperpolarizing current, resulting in a non-ohmic behavior of the current/voltage (I/V) relationship in hyperpolarizing direction. The underlying time-dependent membrane current was first characterized in photoreceptors of the rods as cesium (Cs^+)-sensitive inward current which is triggered by hyperpolarization and may depolarize the membrane. This leads to the typical sequence of an initial transient hyperpolarization by exposure, followed by a slow depolarization (Attwell and Wilson, 1980; Bader et al., 1982; Bader et al., 1979; Fain et al., 1978).

The current in the photoreceptors was designated as I_h because it is activated by hyperpolarization. At about the same time a similar ion current was discovered in the heart, in the pacemaker cells of the sinus node and in the Purkinje fibers of the mammalian heart (Brown and DiFrancesco, 1980; Brown et al., 1979; DiFrancesco, 1981a; DiFrancesco, 1981b; Yanagihara and Irisawa, 1980), and it became clear that the slow inward current is accompanied by sodium and potassium ions. This current was called "funny" current (I_f) to emphasize its unusual behavior, i.e., the fact that an inward current is concerned which is activated by hyperpolarization and, oddly enough, was similar to the previously described K^+ conductance I_{K2}. There is a growing interest in said current because it participates, for instance, in the generation and control of spontaneous activity of the heart.

Further evidence of the presence of a corresponding current in central neurons was found, and it was mentioned by Halliwell and Adams (1982) for the first time. They observed a slow inward current, which was designated as "queer" current (I_q), in pyramidal cells of the hippocampus after hyperpolarization. Subsequently, currents with similar characteristics were found in a great number of neuronal and non-neuronal cells, and said hyperpolarization-activated current was finally recognized as an omnipresent phenomenon in cells of the nerve system. The designation as "I_h" is now accepted as a term for describing said current.

Although it was first assumed that the activity of the respective I_h channels is not modulated, more and more data show that the I_h channels are important targets for neurotransmitters and messenger systems, which emphasizes their important physiological role in the control of cellular electrical activities.

In the meantime it has become known that I_h significantly contributes to the rest potential, limits an excessive hyperpolarization, determines the form of action patterns (firing patterns) and takes part in the generation of rhythmic oscillations of the membrane potential. I_h currents have a few special characteristics that distinguish the same from other voltage-controlled ion channels. Like voltage-controlled Na^+, Ca^{2+} and specific K^+ currents, they have a steep voltage-dependence curve and activate with a sigmoidal time course; they are however activated by hyperpolarization and deactivate by sigmoidal kinetics.

The activation in negative potentials and the blockage by Cs^+ ions reminds of inwardly rectifying K^+ channels. However, many characteristics of I_h clearly differ from that K^+ channel family: The activation kinetics is slower, the activation range is more positive and is independent of the extracellular K^+ concentration, conductance is substantially resistant to extracellular Ba^{2+} ions and the I_h channels are permeable not only to K^+ ions,

but also to Na^+ ions. In contrast to other cation channels, such as ligand-controlled cation channels, the I_h channels are very selective for Na^+ and K^+ ions and have a steep voltage-dependent control.

Of particular importance to the present research work is the participation of the I_h channels in the pacemaker function in the cardiac muscle. The pacemaker activity in the heart is due to specialized myocytes that are located in specific regions of the heart (*sinus venosus*) and are characterized by their ability to beat spontaneously even if separated from the rest of the cardiac muscle. In pacemaker cells of the sinus node in mammals, the spontaneous activity follows from a typical phase of their action potential, the slow diastolic depolarization. During said phase, which corresponds to the diastole of the cardiac contraction cycle, the membrane depolarizes again at a slow pace after termination of the action potential until the threshold value for the generation of a new action potential is reached. Thus the diastolic depolarization is responsible for the initiation of the rhythmic behavior and characterizes action potentials of the sinus node and other spontaneously active cardiocytes.

Apart from the generation of a rhythmic activity, the diastolic (or pacemaker) depolarization takes part in the control of the heartbeat frequency by autonomous neurotransmitters. It is known that the stimulation of the sympathic and parasympathic nerve system leads to an acceleration and deceleration of the heartbeat.

It has become known in the meantime that the I_h channels take part in this pacemaker function. The I_h current of the sinus node is an unspecific cation current, normally accompanied by Na^+ and K^+, which after hyperpolarization slowly activates in a voltage range encompassing that of the diastolic depolarization. The I_h features are well suited for producing a depolarization process as a reaction to a hyperpolarization in a voltage range in which the I_h channel is activated.

So far, however, it has not been possible to identify sequences of genes coding for I_h ion channels. Furthermore, channel protein has so far not been available in a sufficient amount for characterizing the same biochemically. Finally, the pharmacological characterization of I_h channels has so far been extremely difficult because the I_h currents were identified on whole cells, which additionally exhibit K^+- and Na^+-selective conductivities, and were experimentally isolated from the other currents.

It has therefore been the object of the present invention to indicate the nucleic acid, to show its possible applications, and to provide the protein in a functional state and in a sufficient amount for biochemical analyses and pharmaceutical applications.

Said object is achieved by the subject matter of the independent claims. Advantageous developments are indicated in the dependent claims.

The terms used hereinafter shall have the following meanings:

"I_h ion channel" is here to stand for those ion channels that (1) open by hyperpolarization and are closed at more positive voltage values ($V_m \geq$ -10 mV); (2) whose activation and deactivation take place with a relatively slow sigmoidal time course; (3) conduct not only K^+ ions, but also Na^+ ions; (4) are almost entirely blocked by 0.1 – 3 mM extracellular Cs^+ and (5) are directly modulated by cyclic nucleotides, in particular cyclo AMP and cyclo GMP.

"Stringent conditions" means hybridization with 0.1-5 x SSC, preferably 1-2 x SSC, at 60-70°C, preferably 65°C.

"Conditions of low stringency" means hybridization at 0.1-5 x SSC, preferably 1-2 x SSC at 50-60°C, preferably at 55°C.

"Parts" of the I_h ion channel means a section of the protein sequence suited as antigenic determinant, for example, a section of at least 6 amino acids. Sections that occur in the form of domains, such as the sections S1, S2, etc. as indicated in Fig. 1A, are also regarded as parts. This encompasses sections of the ion channel that derive from the DNA sequences indicated in SEQ ID NO 1 to 15 using the IUPAC code, namely by way of amino acid exchanges, deletions and additions, while maintaining the biological function.

"Part" thereof in connection with the nucleic acid means a fragment having a length of at least 6 nucleotides, preferably 12 nucleotides, particularly preferably a length of 18 nucleotides. The part is suited for hybridizing via oligonucleotide hybridization specifically (selectively) with the corresponding total sequence. Thus a "part" of the nucleic acid is a section from the sequences according to SEQ ID NO 1 to 15 that is suited for selectively hybridizing with one of the said sequences.

"Selectively" (specifically) means that under suitable hybridization conditions a nucleic acid only hybridizes with one nucleic acid as is indicated by one of the sequences according to SEQ ID NO 1 to 15, whereas it does not hybridize with another nucleic acid of the respective host organism with which it is normally associated.

"Homology" as is here used is calculated as follows: The amino acids are counted in the sequences or sequence sections to be compared that are either identical or similar at the respective position. This number is divided by the total number of the amino acid residues and multiplied by 100. This yields a percentage of the sequence similarity or homology. This is illustrated by the sample given below:

TWALFKALSHMLCIGYGKFPPQS
PDAFWWAVVTMTTVGYGDMTPVG

The total number of the positions to be compared with one another is 23 residues; there are 7 identically and 6 similarily occupied amino acid positions. That is why the homology (7 + 6)/23 x 100 = 56.5%. An exchange of similar amino acids is also designated as a conservative exchange (cf. Dayhoff et al., 1978).

Insert 1

According to claim 1 there is provided a nucleic acid which comprises at least a part of the sequence of an I_h ion channel. The nucleic acid complementary thereto is also regarded as an inventive embodiment. Said nucleic acid may preferably be derived from a human DNA and is then in particular characterized by the sequences according to SEQ ID NO 1, SEQ ID NO 10, SEQ ID NO 11 and SEQ ID NO 15.

Advantageously, the sequence may also be derived from a rat DNA and is then in particular characterized by the SEQ ID NO 2 and SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 13 and SEQ ID NO 14.

In a further preferred embodiment, the sequence may be derived from a bovine DNA and is then characterized by the sequences according to SEQ ID NO 3 and SEQ ID NO 6, SEQ ID NO 7 and SEQ ID NO 12.

Furthermore, the sequence may preferably be derived from a sea urchin DNA, and it is then preferably characterized by the sequence SEQ ID NO 4.

Furthermore, the DNA may preferably be derived from *Drosphophila melanogaster.* The complete sequence is then in accordance with SEQ ID NO 5.

Insert 1:

The above isolated or purified nucleic acid molecules also can be characterized in terms of "percentage of sequence identity." In this regard, a given nucleic acid molecule as described above can be compared to a nucleic acid molecule encoding a corresponding gene (i.e., the reference sequence) by optimally aligning the nucleic acid sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence, which does not comprise additions or deletions, for optimal alignment of the two sequences. The percentage of sequence identity is calculated by determining the number of positions at which the identical nucleic acid base occurs in both sequences, i.e., the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity. Optimal alignment of sequences for comparison may be conducted by computerized implementations of known algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI, or BlastN and BlastX available from the National Center for Biotechnology Information, Bethesda, MD), or by inspection. Sequences are typically compared using BESTFIT or BlastN with default parameters.

"Substantial sequence identity" means that at least 75%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% of the sequence of a given nucleic acid molecule is identical to a given reference sequence. Typically, two polypeptides are considered to be substantially similar if at least 40%, preferably at least 60%, more preferably at least 90%, and most preferably at least 95% of the amino acids of which the polypeptides are comprised are identical to or represent conservative substitutions of the amino acids of a given reference sequence.

One of ordinary skill in the art will appreciate, however, that two polynucleotide sequences can be substantially different at the nucleic acid level, yet encode substantially similar, if not identical, amino acid sequences, due to the

degeneracy of the genetic code. The present invention is intended to encompass such polynucleotide sequences.

A particularly preferred embodiment comprises sequences that exhibit a homology of at least 80% to one of the sequences with the SEQ ID NO 1 to 15. In a further preferred embodiment the sequence exhibits a homology of at least 90% to one of the sequences designated by SEQ ID NO 1 to 15.

It hybridizes in a particularly preferred manner under low stringent conditions and even more preferably under conditions of high stringency with one of the sequences designated by SEQ ID NO 1 to 15.

The present invention covers modifications of the sequences according to SEQ ID NO 1 to 15 which result e.g. from the degeneration of the genetic code, deletions, insertions, inversions and further mutations, the biological property of the encoded channel protein or part thereof being preferably maintained.

Furthermore, the invention relates to an mRNA molecule comprising a sequence corresponding to one of the above-described sequences. Accordingly the invention covers a polypeptide which is encoded by the above-mentioned nucleic acid.

Insert 2

The above-described sequences can be used for a screening method or also a diagnosing method. In a screening method, it is possible owing to the identification of the sequence of the I_h channel to test the effect of substances on ion channels using said sequences.

Such a screening method may e.g. comprise the following steps:

Insert 2:

A nucleic acid molecule as described above can be cloned into any suitable vector. The selection of vectors and methods to construct them are commonly known to persons of ordinary skill in the art and are described in general technical references (see, in general, "Recombinant DNA Part D," *Methods in Enzymology*, Vol. 153, Wu and Grossman, eds., Academic Press (1987); Birren et al., *Genome Analysis: A Laboratory Manual Series, Volume 1, Analyzing DNA*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1997); Birren et al., *Genome Analysis: A Laboratory Manual Series, Volume 2, Detecting Genes*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1998); Birren et al., *Genome Analysis: A Laboratory Manual Series, Volume 3, Cloning Systems*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1999); Birren et al., *Genome Analysis: A Laboratory Manual Series, Volume 4, Mapping Genomes*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1999); and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)). Desirably, the vector comprises regulatory sequences, such as transcription and translation initiation and termination codons, which are specific to the type of host into which the vector is to be introduced, as appropriate and taking into consideration whether the vector is DNA or RNA. Preferably, the vector comprises regulatory sequences that are specific to the genus of the host. Most preferably, the vector comprises regulatory sequences that are specific to the species of the host.

Constructs of vectors, which are circular or linear, can be prepared to contain an entire nucleic acid sequence as described above or a portion thereof ligated to a replication system functional in a prokaryotic or eukaryotic host cell. Replication systems can be derived from ColE1, 2 mμ plasmid, λ, SV40, bovine papilloma virus, and the like.

In addition to the replication system and the inserted nucleic acid, the

construct can include one or more marker genes, which allow for selection of transformed or transfected hosts. Marker genes include biocide resistance, e.g., resistance to antibiotics, heavy metals, etc., complementation in an auxotrophic host to provide prototrophy, and the like.

Suitable vectors include those designed for propagation and expansion or for expression or both. A preferred cloning vector is selected from the group consisting of the pUC, series the pBluescript series (Stratagene, LaJolla, CA), the pET series (Novagen, Madison, WI), the pGEX series (Pharmacia Biotech, Uppsala, Sweden), and the pEX series (Clonetech, Palo Alto, CA). Bacteriophage vectors, such as λGT10, λGT11, λZapII (Stratagene), λ EMBL4, and λ NM1149, also can be used. Examples of plant expression vectors include pBI101, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clonetech, Palo Alto, CA). Examples of animal expression vectors include pEUK-C1, pMAM and pMAMneo (Clonetech).

An expression vector can comprise a native or nonnative promoter operably linked to an isolated or purified nucleic acid molecule as described above. The selection of promoters, e.g., strong, weak, inducible, tissue-specific and developmental-specific, is within the skill in the art. Similarly, the combining of a nucleic acid molecule as described above with a promoter is also within the skill in the art.

Thus, in view of the above, the present invention also provides a host cell comprising an isolated or purified nucleic acid molecule or a vector as described above. Examples of host cells include, but are not limited to, a human cell, a human cell line, *E. coli, B. subtilis, P. aerugenosa, S. cerevisiae,* and *N. crassa.* Other examples include *E. coli* TB-1, TG-2, DH5α, XL-Blue MRF' (Stratagene), SA2821 and Y1090.

- producing homogeneous channel preparations, for example, by expression of the above-mentioned nucleic acid in a suitable host, such as oocytes, mammalian cells, etc.,

- testing of substances on said channel preparations.

It can here be determined by measuring the channel activity under the action or in the absence of test substances which substances are suited for influencing the channels.

The invention also relates to a kit for performing such a screening method which comprises at least one of the above-described nucleic acids or polypeptides.

The sequences can also be used for a diagnosing method, in particular for recognizing cardiovascular disorders.

In said diagnosing method the nucleic acid of the patient is preferably contacted with a sequence section of one of the above-described DNAs and/or RNAs, whereby a signal is obtained that is indicative of the presence and/or absence of an ion-channel nucleic acid sequence. Mutations in the ion channels of the patient can also be detected by selecting suitable samples, e.g. short oligonucleotides, which in turn is of help to the differential diagnosis.

Furthermore, the present invention refers to a kit for carrying out such a diagnosing method comprising one of the above-described sequences.

Furthermore, it is possible to use the above-described sequences for the treatment and/or prophylaxis of cardiovascular disorders and disturbances of consciousness as well as pain states. In a preferred embodiment, cardiovascular disorders that are due to

a faulty control of the sinus node can be treated or recognized at an early stage. Furthermore, disturbances of consciousness that are due to a malfunction of cortico-thalamic neurons are preferably recognized. For instance, within the scope of gene therapy, a fully operable ion channel as encoded by the nucleic acids described herein are introduced into a patient to replace a channel that is no longer operative.

Insert 3

Lastly, the invention relates to a pharmaceutical composition which comprises one or more of the above-described nucleic acids or the above-described polypeptide. Such a pharmaceutical composition can be used for treating cardiovascular disorders, in particular those that are due to a faulty control of the sine node, as well as disturbances of consciousness, in particular those caused by a malfunction in cortico-thalamic neurons.

Insert 4

The invention shall now be described with reference to the examples and the attached figures, of which:

Figure 1A shows the nucleic-acid and the derived protein sequence of the channel from sea urchin *Strongylocentrotus purpuratus* (SPHI channel).

Figure 1B shows the S4 motif of said channel protein, as compared with other known channel sequences;

Figure 1C shows the pore motif of said sequence as compared with other sequences of other channels;

Figure 1D shows the cNMP-binding domain of the cDNA of the I_h ion channel as compared with other sequences of ion channels;

Insert 3:

Accordingly, the present invention provides a method of prophylactically or therapeutically treating a mammal for a cardiovascular disorder, in particular a cardiovascular disorder that is due to a faulty control of the sinus node. The method comprises administering to a mammal (i) a vector comprising and expressing a prophylactically or therapeutically effective amount of an above-described nucleic acid or (ii) a prophylactically or therapeutically effective amount of an above-described polypeptide, whereupon the mammal is treated for the cardiovascular disorder.

The present invention further provides a method of prophylactically or therapeutically treating a mammal for a disturbance of consciousness, in particular a disturbance of consciousness that is due to a malfunction in thalamic neurons. The method comprises administering to a mammal (i) a vector comprising and expressing a prophylactically or therapeutically effective amount of an above-described nucleic acid or (ii) a prophylactically or therapeutically effective amount of an above-described polypeptide, whereupon the mammal is treated for the disturbance of consciousness.

Still further provided by the present invention is a method of prophylactically or therapeutically treating a mammal for a pain state. The method comprises administering to a mammal (i) a vector comprising and expressing a prophylactically or therapeutically effective amount of an above-described nucleic acid or (ii) a prophylactically or therapeutically effective amount of an above-described polypeptide, whereupon the mammal is treated for the pain state.

Insert 4:

Therefore, the present invention also provides a composition comprising an above-described isolated or purified nucleic acid (or vector comprising the nucleic acid) or an above-described polypeptide and a carrier therefor. Carriers, such as pharmaceutically acceptable carriers, are well-known in the art, and are readily available. The choice of carrier will be determined in part by the particular route of administration and whether a nucleic acid molecule or a polypeptide moleculeis being administered. Accordingly, there is a wide variety of suitable formulations for use in the context of the present invention, and the invention expressly provide a pharmaceutical composition that comprises an active agent of the invention and a pharmaceutically acceptable carrier therefor. The following methods and carriers are merely exemplary and are in no way limiting.

Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluent, such as water, saline, or orange juice; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth. Pastilles can comprise the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients/carriers as are known in the art.

Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The

formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Further suitable formulations are found in Remington's Pharmaceutical Sciences, 17th ed., (Mack Publishing Company, Philadelphia, Pa.: 1985), and methods of drug delivery are reviewed in, for example, Langer, Science, 249, 1527-1533 (1990).

Generally, when an above-described polypeptide is administered to an animal, such as a mammal, in particular a human, it is preferable that the polypeptide is administered in a dose of from about 1 to about 1,000 micrograms of the polypeptide per kg of the body weight of the host per day when given parenterally. However, this dosage range is merely preferred, and higher or lower doses may be chosen in appropriate circumstances. For instance, the actual dose and schedule can vary depending on whether the composition is administered in combination with other pharmaceutical compositions, or depending on interindividual differences in pharmacokinetics, drug disposition, and metabolism. One skilled in the art easily can make any necessary adjustments in accordance with the necessities of the particular situation.

If desired, the half-life of the polypeptide can be increased by conjugation to soluble macromolecules, such as polysaccharides, or synthetic polymers, such as polyethylene glycol, as described, for instance, in U.S. Patents 5,116,964, 5,336,603, and 5,428,130. Alternately, the polypeptides can be "protected" in vesicles composed of substances such as proteins, lipids (for example, liposomes), carbohydrates, or synthetic polymers. If liposomes are employed, liposome delivery can be carried out as described in U.S. Patent 5,468,481, or using liposomes having increased transfer capacity and/or reduced toxicity *in vivo* (see, e.g., PCT patent application WO 95/21259 and the references cited therein). Furthermore, polypeptides can be administered in conjunction with adenovirus (preferably replication-deficient adenovirus) to allow the intracellular uptake of the polypeptides by adenoviral-mediated uptake of bystander molecules (e.g.,

as described in PCT patent application WO 95/21259). Similarly, a conjugate, such as one comprising a targeting moiety, or a fusion of a an above-described polypeptide to an antibody (or an antigenically reactive fragment thereof) that recognizes a cell surface antigen; etc. can be employed to deliver the resultant fusion protein to a specific target cell or tissue (e.g., as described in U.S. Patent 5,314,995).

Those of ordinary skill in the art can easily make a determination of the vector to be administered to an animal, such as a mammal, in particular a human. The dosage will depend upon the particular method of administration, including any vector or promoter utilized. For purposes of considering the dose in terms of particle units (pu), also referred to as viral particles, it can be assumed that there are 100 particles/pfu (e.g., $1x10^{12}$ pfu is equivalent to $1x10^{14}$ pu). An amount of recombinant virus, recombinant DNA vector or RNA genome sufficient to achieve a tissue concentration of about 10^2 to about 10^{12} particles per ml is preferred, especially of about 10^6 to about 10^{10} particles per ml. In certain applications, multiple daily doses are preferred. Moreover, the number of doses will vary depending on the means of delivery and the particular recombinant virus, recombinant DNA vector or RNA genome administered.

Further provided by the present invention is a hybridoma cell line that produces a monoclonal antibody that is specific for an above-described isolated or purified polypeptide molecule. Methods of making hybridomas are known in the art (see, e.g., Harlow et al., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988); Harlow et al., *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1999)). Thus, the present invention also provides the monoclonal antibody produced by the hybridoma cell line. Similarly, the present invention provides a polyclonal antiserum raised against an above-described isolated or purified polypeptide molecule. Methods of raising polyclonal antiserum against a polypeptide molecule are also known in the art (see, e.g., Harlow et al.(1988), *supra*; Harlow et al.(1999), *supra*).

Figure 2A shows the inward current having a complex waveform, which is triggered by the hyperpolarizing voltage steps from a holding voltage of +10 mV to more negative test values;

Figure 2B shows the equilibrium current/voltage (I/V) relationship determined at the end of a hyperpolarizing voltage pulse;

Figure 2C shows the measuring protocol for the determination of the "instantaneous" I/V relationship from the amplitude of the tail currents;

Figure 2D shows the "instantaneous" I/V relationship which is slightly outwardly rectifying, at a reversal voltage V_{rev} of –30 mV;

Figure 2E shows that the time course of the "tail" currents depends on the time of the change in voltage;

Figure 2F shows the voltage dependence of the relative probability that the channel is open, P_o, which was determined from the amplitude of tail currents at +10 mV, similar to those illustrated in Fig. 2A;

Figure 3A shows the induction of large whole-cell currents by hyperpolarization in the presence of 1 mM cAMP, which currents developed with a delay and slowly reached an equilibrium;

Figure 3B shows the voltage dependence of P_o, determined from normalized whole-cell "tail" currents and "tail" currents of inside-out patches;

Figure 3C shows the rapid rise in amplitude of the inward current after short UV exposure;

Figure 3D shows SPIH currents of cell-free membrane pieces without cAMP; and

Figure 3E shows the same as Fig. 3D, but with cAMP;

Figure 3F shows the dependence of the current on the cAMP concentration which can be described by a simple binding isotherm with $K_{1/2}$ of 0.74 µM and a Hill coefficient which does not clearly differ from one;

Figures 4A and 4B show the blockade of the SPIH channels by Cs^+ (Figure 4A control, Figures 4B + 10 mM Cs^+);

Figure 4C shows the I/V relationship in the presence of 0 to 10 mM Cs^+;

Figure 4D shows a plot of standardized current I/I_{max} (at –70 mV) against Cs^+;

Figure 4E shows the ion selectivity of SPIH channels on inside-out patches, in the case of which 100 mM of the bath K^+ were replaced by corresponding concentrations of Rb^+, Na^+, Li^+ or Cs^+;

Figure 4F shows the I/V relationship under the various ionic conditions shown in part E;

Figure 4G shows that the inward currents were interrupted almost entirely, whereas the amplitudes of the outward currents did not change when the extracellular medium just contained Na^+;

Figure 4H shows the I/V relationship of the currents from part G at different K^+ concentrations;

Figure 5A shows a Northern Blot of the channel messenger RNA with a major transcript of about 3.3 kb and a minor transcript of 2.9 kb;

Figure 5B is a light-microscopic photograph of sperms from *S. purpuratus* (right picture) and the corresponding immunohistochemical staining with an antibody which specifically recognizes the SPIH channel (left picture).

Figure 5C shows a corresponding Western Blot analysis.

Figure 6 is a schematic illustration showing the pc SPIH construct that was used for the heterologous expression of SPIH in HEK 293 cells. The cDNA region is illustrated as a hatched bar; the adjoining regions of the plasmid vector (pcDNA I) as bold lines. The orientation of the cDNA in the plasmid vector can be inferred from the position of the promoter for the T7 polymerase and the restriction sites in the multiple cloning region. The inserted Kozak sequence is designated by K.

A typical representative of an ion channel protein according to the invention is the channel from sea urchin (SPIH). The channel activity of HEK 293 cells, which had been transfected with the pcSPHI construct (Fig. 6), was examined with the help of the patch-clamp method in the whole-cell configuration. Hyperpolarizing voltage steps showed an inward current with a complex waveform (cf. Fig. 2A). A fast current component that was not time-resolved was followed by a time-dependent current that developed with a delay and, after the maximum had been reached, decreased into smaller amplitudes when the test voltage was $V_m \leq -30$ mV (Fig. 2A). After V_m had been set back to +10 mV, "tail" currents developed that also showed a complex time course. The steady-state

relationship between current/voltage (I/V), at the end of the hyperpolarizing voltage pulse (arrow in Fig. 2A), showed a strong inward rectification (Fig. 2B). The "instantaneous" I/V relationship was determined from the amplitude of the tail currents using a different protocol for the voltage steps (Fig. 2C). The "instantaneous" I/V relationship was slightly outwardly rectifying with a reversal voltage, V_{rev}, of –30 mV (Fig. 2D). The I/V relationship became approximately linear at higher $[K^+]_o$ because the inward sodium current was significantly amplified by $[K^+]_o$ (see Fig. 4H). The conclusion can be drawn that the currents are strongly inwardly rectifying because the SPIH channel at positive voltages is either closed or inactivated. The voltage dependence of the open probability, P_o (Fig. 2F), was determined from the amplitude of the tail currents at +10 mV (Fig. 2A). The voltage, $V_{1/2}$, at which a half-maximal current was observed, was at –26.1 mV (7 experiments). Thus the SPIH channel is inactive at voltages $\geq$ +10 mV and is opened by hyperpolarization. This voltage dependence reminds of hyperpolarization-activated currents (I_h) which occur in different cells (DiFrancesco, 1990, 1993; Pape, 1996). Because of its unusual properties, the I_h has also been designated as a "queer" or "funny" current (I_q and I_f). The channel according to the invention is (1) activated at hyperpolarizing voltages; (2) directly modulated by cyclic nucleotides; (3) blocked by millimolar concentrations of extracellular Cs^+; (4) it is cation-selective at a P_{Na}/P_K of ~ 0.2 to 0.4; and (5) the inward sodium currents are sensitive to $[K^+]_o$. The following experiments demonstrate that said features are also found in the heterologously expressed SPIH channel.

With 1 mM cAMP in the pipette solution, hyperpolarization produced large currents which developed with a delay and slowly reached a steady state (Fig. 3A).The sigmoidal time course of the current (see Fig. 3A, box) is characteristic of the time course of vertebrate I_h currents. 1 mM cGMP in the pipette also changed the SPIH-induced currents. The voltage dependence of P_o was determined with the help of whole-cell tail currents (Fig. 3B). A fit to the Boltzmann equation yielded $V_{1/2}$ = -50.8 mV. The dialysis of the cell with

the pipette solution took several minutes; thus transient effects of cAMP might impair the test. A technique was therefore employed using the rapid photorelease of cAMP or cGMP from "caged" derivatives (cf. Adams and Tsien, 1993; Hagen et al., 1996). The cells were dialyzed with 100 µm "caged" cAMP and the SPIH channels were activated by changing the V_m from +10 mV to -70mV; a short flash of UV light then effected a rapid increase in the amplitude of the SPIH-induced inward current (Fig. 3C). The hyperpolarization-activated currents before the flash resembled control currents (Fig. 3C, trace 1), while amplitude and time course of the currents after the UV flash (Fig. 3C, trace 2) were similar to those recorded in the presence of cAMP (Fig. 3E). With 100 µM "caged" cGMP in the pipette, UV flashes of similar duration and similar intensity did not change the SPIH-induced currents. A binding motif for cyclic nucleotides suggests that cAMP could directly enhance the channel activity without the participation of a phosphorylation mechanism. To verify this hypothesis the SPIH currents were measured on excised membrane patches without (Fig. 3D) and with cAMP (Fig. 3E). cAMP (1mM) enhanced the amplitudes of the voltage-activated currents by up to 20-fold. The increase in current by cAMP was reversible and did not require Mg^{2+}/ATP. The superfusion of the excised membrane patches with solutions containing different cAMP concentrations enhanced the SPIH currents in a dose-dependent way. The dependence of the current on the cAMP concentration can be described by a simple binding isotherm with a $K_{1/2}$ of 0.74 µM and a Hill coefficient which does not significantly differ from one (Fig. 3F). In the separated membrane patches, $V_{1/2}$ in the presence of cAMP was about 35 mV more negative than $V_{1/2}$ measured in the whole-cell configuration (Fig. 3B). This observation might suggest that an endogenous factor provided by the HEK293 cell also determines $V_{1/2}$. cGMP concentrations of up to 1mM did not change the amplitude of the SPIH currents. The conclusion can be drawn from this experiment that cAMP, but not cGMP, can modulate the SPIH channel activity. Thus, in contrast to CNG channels (Finn et al., 1996) SPIH is under the double control of voltage and cAMP. Blockage of the SPIH channels by extracellular Cs^+ was examined on "outside-out" membranes with the

voltage protocol of Fig. 2C. Cs^+ blocked the SPIH channel in a concentration- and voltage-dependent manner. In the presence of 10 mM Cs^+ the inward currents disappeared completely, whereas outward tail currents were still present (cf. Figs. 4A and 4B). The I/V relationship in the presence of from 0 to 10 mM Cs^+ is shown in Fig. 4C. The standardized current I/I_{max} (at –70 mV) was plotted against [Cs^+] (Fig. 4D). The data were fitted with an inhibitory constant K_i of 245 µM and a Hill coefficient of n = 1.2. The ion selectivity of the SPIH channel was determined with inside-out membranes. The bath solutions always contained 0.1 mM cAMP to increase the amplitude of the currents. 100 mM K^+ in the bath were replaced by Rb^+, Na^+, Li^+ or Cs^+ (Fig. 4E). The permeability ratios $P_K : P_{Rb} : P_{Na} : P_{Li} : P_{Cs}$ were calculated as 1 : 0.7 : 0.26 : 0.15 : 0.06. The ion selectivity of SPIH concurs well with the ion selectivity of various vertebrate I_h channels (Pape, 1996; Wollmuth and Hille, 1992). When the extracellular medium only contained Na^+, the inward currents were eliminated almost entirely, whereas the amplitudes of the outward currents did not change significantly (Fig. 4G). Elevation of $[K^+]_o$ to 5 and 20 mM dramatically increased the inward currents. These results demonstrate that the SPIH channel conducts little, if any, sodium in the absence of potassium ions.

The expression of messenger RNA of the channel protein was analyzed by means of Northern Blots. A major transcript of around 3.3 kb and a minor transcript of 2.9 kb were detected in poly(A)$^+$RNA of male, but not female, gonads (Fig. 5A). The size of the transcripts concurs well with the size of the cloned cDNA (3 kb). The SPIH-specific probe did not hybridize with poly(A)$^+$RNA isolated from the intestine of sea urchin (Fig. 5A). The exclusive expression of SPIH mRNA in male gonads suggests that the channel is expressed in sperms. This hypothesis was tested with purified antibodies FPc44K and FPc45K directed against a fusion protein of the C-terminal domain of the channel polypeptide (residues 662-767). The antibodies were used for Western Blot analyses (Fig. 5C) and immunocytochemistry (Fig. 5B). Both antibodies recognized a main band of M_r ~ 92K in Western Blots of flagellar membranes which had been purified from sea

urchin sperm (Fig. 5C, lane 3). Membranes which had been purified from the sperm head were not recognized by the antibodies (Fig. 5C, lane 5). This result was confirmed by immunocytochemistry with individual sperms. The antibody FPc45K almost exclusively stained the sperm flagellum (Fig. 5B); the weak staining of some head structures presumably represents unspecific cross reactivity of the antibody. A band of M_r ~ 88K was observed in Western Blots of membranes of transfected HEK293 cells (Fig. 5C, lane 2). The M_r of the channel polypeptide, expressed in HEK293 cells, is almost identical with the M_r value as is to be expected of the derived amino acid sequence (87.9K). In membranes of non-transfected HEK293 cells, no 88K polypeptide was detected by the antibody (Fig. 5C, lane 1). The treatment of flagellar membranes with alkaline phosphatase lowered the M_r of the native polypeptide from ~ 92 K to 88K. Since native and heterologously expressed polypeptides were of a similar size, the cloned cDNA carries the complete coding sequence of SPIH. The small decrease in M_r under dephosphorylating conditions demonstrates that the native polypeptide in phosphorylated form is present with a slightly reduced electrophoretic mobility. In most dephosphorylation experiments the shift from 92K to 88K was not complete, and at least two intermediate bands were observed. This result suggests that the channel poplypeptide should be phosphorylated several times. The SPIH sequence carries sequence motifs for the phosphorylation by PKA, PKG, PKC and tyrosine kinase (see Fig. 1A).

The electrophysiological properties unequivocally identify SPIH as a member of the I_h channel family. However, we also noticed characteristic differences between SPIH and vertebrate I_h channels. First, in the absence of cAMP the SPIH current is transient, whereas in the presence of cAMP the time course is similar to that in vertebrate I_h channels. Second, the large augmentation of the SPIH current by cAMP primarily arises from an increase in the maximum current while cAMP modulates the cardiac I_h channel such that $V_{1/2}$ is shifted towards more positive values (DiFrancesco, 1993) without

influencing the maximum amplitudes (see, however, Ingram and Williams, 1996; Accili et al., 1997). Finally, the cardiac I_h is also modulated by micromolar cGMP concentrations (DiFrancesco and Tortora, 1991), whereas SPIH does not exhibit said effect. The SPIH channel is very similar to both the voltage-controlled K^+ channels and the CNG cation channels. That is why the I_h channels form a class of their own within the superfamily of the voltage-controlled channels. SPIH has a characteristic motif of a voltage sensor (S4) like the K^+, Na^+ and Ca^{2+} channels that are opened by depolarization. Although there is no a priori reason to rule out the S4 motif as a voltage sensor in a hyperpolarization-activated channel, the mechanism of an activation as in HERG-K^+ channels (Trudeau et al., 1995; Smith et al., 1996) is more likely. It has been demonstrated with respect to the strong inward rectification of HERG that it is the result of the inactivation which closes the channels at positive voltages, but the channels recover rapidly from the inactivation at negative voltages. In HERG channels the inactivation is much faster than the activation and is therefore not visible kinetically (Smith et al., 1996). Together with the CNG channels SPIH possesses a cyclic nucleotide-binding region, and its properties are modulated by cAMP. cAMP probably intensifies the SPIH activity by binding to the highly conserved cyclic nucleotide-binding region. In CNG channels, it has been demonstrated with respect to the high selectivity for cGMP that said selectivity is accompanied by a Thr residue (T363 in the α-subunit of the rod photoreceptor; Altenhofen et al., 1991) and an Asp residue (D604 in rCNGα; Varnum et al., 1995). The SPIH has Val and Ile residues at the corresponding positions; it is presumed that these positions also control the ligand selectivity in SPIH. The physiological importance of the I_h channels in flagellar membranes of sperm could be explained as follows: the stimulation of *S. purpuratus* sperm with the chemotatic peptide "speract" causes a hyperpolarization (Lee and Garbers, 1986; Garbers, 1989), of which it is assumed that it is due to the opening of a K^+ channel (Babcock et al., 1992). At higher peptide concentrations the hyperpolarization is followed by a depolarization (Babcock et al, 1992). Two (or more) ion channel types with different selectivity and pharmacology could contribute to the "speract"-induced

depolarization (see Darszon et al, 1996). One of said channels has a weak K^+ selectivity ($P_{Na/Pk} \cong 0.2$) and an extremely low P_o (at $V_m = 0$ mV) which is considerably enhanced by cAMP, but not by cGMP (Labarca et al., 1996). These observations suggest that said channel is actually SPIH. The "speract"-induced hyperpolarization could initiate the SPIH channel activity which then could even be augmented by a simultaneous increase in the cAMP level (Hansbrough et al., 1980) with the help of a voltage-dependent adenylate cyclase (Beltrán et al, 1996). At the given ionic composition of sea water and a P_{Na}/P_K of 0.2 to 0.4 the opening of the SPIH channel and the subsequent Na^+ influx could effect the "speract"-induced depolarization. It can also reasonably be assumed that the I_h channels, for instance in cardiac cells or thalamic neurons, take part in the generation of oscillations of the membrane voltage, thereby causing the oscillation of Ca^{2+} in the flagellum (Suarez et al, 1993). The change in $[Ca^{2+}]_i$, could change the flagellar beating, thereby contributing to the chemotactic response.

EXAMPLES

Methods

Isolation of the cDNA clones

With two degenerated primers (# 1764 and # 1772) a PCR was carried out on single-strand cDNA (from sea urchin gonads, *Drosophila melanogaster*, bovine retina, olfactory tissue of the rat) or on cDNA libraries (from human thalamus or heart). A 100 µl PCR batch had the following composition: 3-10 ng of first-strand cDNA and about 10^5 pfu of the cDNA libraries, respectively, 1.6 µg of the degenerated primer each, 1 x PCR buffer, 2mM dNTP, 1 U PrimeZyme (Biometra). The PCR batch was first denatured at 94°C for 2 min and then incubated for 45 cycles in the following manner:

denaturation:	94°C, 45 sec
hybridization:	48°C, 45 sec
polymerization:	72°C, 40 sec

The sequences of the degenerated primers are (in 5'→3' direction):

1764: CTGACTGCAGARGTNTTYCARCCNGGNGA (SEQ ID NO 16)

1772: ATCGGAATTCNCCRAARTANGANCCRTC (SEQ ID NO 17)

The PCR fragments amplified with the primers # 1764 and # 1772 were radiolabeled and used as probes for screening cDNA libraries under high stringency for the complete cDNAs. The partial clone HHIH (SEQ ID NO 11) was isolated by low-stringency hybridization. The hybridization conditions were as follows:

	high stringency	low stringency
prehybridization	5 x SSC[1], 5 x Denhardt's[2], 0.1% SDS, 0.1 mg/ml herring sperm DNA, 1-2 h, 65°C	5 x SSC[1], 5 x Denhardt's[2], 0.1% SDS, 0.1 mg/ml herring sperm DNA, 1-2 h, 55°C
hybridization	prehybridization solution with 50-100 ng ^{32}P-labeled DNA (1-10^6 cpm/ml), 12-14 h, 65°C	prehybridization solution with 50-100 ng ^{32}P-labeled DNA ($1x10^6$ cpm/ml), 12-14 h, 65°C
washing	1 x SSC(1), 0.1% SDS 2 x 30 min, 65°C	2 x SSC(1), 0.1% SDS 2 x 30 min, 55°C

[1] 1 x SSC 150 mM NaCl, 15 mM Na citrate, pH 7.0

[2] 1 x Denhardt's Ficoll, polyvinylpyrrolidone, bovine serum albumin (0.2 g/l each)

The positive phages were isolated and the cDNA was converted by "in vivo excision" (in case of λZAPII phages) into pBluescriptSK derivatives. The cDNA was excised with EcoRI from λgt11 phages and subcloned into pBluescriptSK plasmid DNA. The DNA was sequenced with the dideoxy-mediated chain termination technique (Sanger et al., 1997).

Northern and Western Blots

Poly(A)$^+$RNA, isolated from different sea urchin tissues, was analyzed by Northern blotting. Each lane contained about 10 µg poly(A)$^+$RNA. The blot was hybridized with a ^{32}P-labeled 1074 bp cDNA fragment (nucleotide positions) at 42°C, 5 x SSC and 50% formamide. A C-terminal region of the SPIH polypeptide was expressed as a fusion construct with the maltose binding protein. The purified fusion protein was used for producing the polyclonal antibodies FPc44K and FPc45K; the antibodies were purified from rabbit serum by affinity chromatography using the fusion protein. Sperm flagella were separated from the head according to Darszon et al. (1994). Purified flagella and

head membranes were homogenized in a solution buffer containing 150 mM NaCl, 1 mM $MgCl_2$, 20 mM Hepes at pH 7.5, 0.1 mM EGTA and 0.5% Triton X-100, followed by a centrifugation at 40,000 rpm for 60 minutes. This process was repeated two times. Transfected HEK293 cells were homogenized in a lysis buffer (10 mM Hepes, 1 mM DTT and 1 mM EDTA at pH 7.4), 5 x freeze-dried (in liquid N_2) and finally centrifuged at 55,000 rpm for 10 minutes. The membrane pellet was dissolved in the solution buffer. Flagellar membrane proteins were dephosphorylated with a unit of alkaline phosphatase in solution buffer at 30°C for 30 to 60 min. The membrane proteins were separated by SDS-PAGE, transferred to Immobilon membranes and labeled with the polyclonal antibodies. The immunoreactivity was made visible by the ECL detection kit (Amersham). Immunocytochemistry on an individual sperm was carried out as described above (Weiner 1997).

Electrophysiology

cDNA coding the SPIH polypeptide was transiently expressed in HEK293 cells, as described earlier (Baumann et al, 1994). SPIH-controlled currents were recorded with the patch-clamp method in the whole-cell configuration and cell-free membrane patches. The composition of various bath and pipette solutions is indicated in the legends of the figures (see below). The channels were activated by stepping the membrane voltage from +10 mV to various negative voltage values. Leakage currents were subtracted using a P/8 protocol. The voltage dependence of the probability that the channel is open was determined from tail currents at +10 mV. The blockade of the SPIH channel by Cs^+ was analyzed with outside-out membrane patches in the presence of 1 mM cAPM in a pipette solution. The solutions in the bath contained 0.03 to 10 mM CsCl. Relative ion permeabilities were calculated from the respective shift of V_{rev}, which was measured on cell-free inside-out membrane patches, when 100 mM K^+ in the bath had been replaced

by Na^+, Li^+, Rb^+ or Cs^+. Experiments with "caged" cAMP or "caged" cGMP were carried out as described earlier (Hagen et al. 1996).

The results of said experiments are now described in more detail.

Figure 1A shows the nucleic acid sequence and the derived amino acid sequence of the I_h channel of sea urchin (SPIH). Nucleotides are numbered in 5'→3' direction, +1 corresponding to the first nucleotide of the start codon (ATG) of the open reading frame. Nucleotides that are 5'-located from nucleotide +1 are designated by negative figures. The derived amino acid sequence (one-letter code) is indicated under the nucleic acid sequence and is also numbered. The start codon (ATG), the corresponding methionine and the stop codon (TGA; pos. 2302-2304) are printed in bold. Stop codons in the same reading frame before the start codon are underlined. The polyadenylation signal at position 2501-2507 is boxed. The position of the transmembranal segments S1-S6, of the pore-forming region and of the binding site for cyclic nucleotides (cNMP binding site) is marked by bars above the nucleic acid sequence. The limits of said regions are defined by sequence comparison with other voltage-dependent K^+ channels, EAG-K^+ channels and CNG channels. Consensus sequences for phosphorylation by cAMP/cGMP-dependent kinases are marked by triangles (Δ). Consensus sequences for phosphorylation by protein kinase C are marked by circles (•) and that by tyrosine kinase by an asterisk (✱). The SPIH sequence (SEQ ID NO 4) codes for a protein of 767 amino acids with a calculated molecular weight of 87,937 Da.

Figure 1B shows a comparison of the voltage-sensor (S4) motifs of the I_h channel of sea urchin and other channels. Regularly spaced Arg or Lys residues are boxed. Other positively charged residues are in bold.

Shaker (Pongs et al., 1988), K^+ channel encoded by the *Drosophila* Shaker gene;

DmEAG (Warmke et al, 1997), *Drosophila* EAG channel;
HERG, human EAG-related gene (Warmke and Ganetzky, 1994);
KAT1 (Anderson et al, 1992), K^+ channel of *Arabidopsis thaliana*;
brCNGCα (Kaupp et al, 1989), α-subunit of the cyclic nucleotide-controlled channel from bovine rod photoreceptors.

Figure 1C shows the pore motif of SPIH with the pore motifs of other members of the superfamily of the voltage- and cyclic nucleotide-controlled ion channels:

The residues which are identical or similar to the corresponding amino acids in SPIH are highlighted by a black or grey background.

Figure 1D shows a sequence comparison of cNMP binding domains.
boCNGCα, the α-subunit of the CNG channel of bovine olfactory neurons (Ludwig et al., 1990); PKA1, the cAMP binding site 1 of the protein kinase A (Titani et al., 1984); the cGMP binding site 1 of the protein kinase G (Takio et al, 1984); CAP, the catabolite activator protein (Aiba et al., 1982). Residues that are highly conserved in cyclic nucleotide-binding motifs are indicated by arrows; residues that determine the ligand selectivity in brCNGCα are indicated by an asterisk. Secondary-structure predictions derived from the cAMP binding domain of CAP are shown as bars below the sequence.

Figure 2 shows the electrophysiological characterization of the SPIH channel.

Figure 2A shows the current, which was recorded by transfected HEK293 cells in the whole-cell configuration. The current was activated by stepping the voltage from a holding value at +10 mV to various test values of -100 mV to +10 mV in increments of 10 mV. Tail currents were recorded by stepping the voltage of the test value back to +10 mV. The HEK293 cells were flushed with a bath solution containing the following (mM):

135 NaCl, 5 KCl, 1.8 $CaCl_2$, 2.8 $MgCl_2$ and 5 Hepes-NaOH at pH 7.4; the pipette solution contained the following substances (mM): 126 KCl, 10 Hepes-KOH, 10 EGTA at pH 7.4.

In **Figure 2B,** there is plotted the voltage-current (I/V) relationship measured under equilibrium conditions at the time indicated by the arrowhead in Figure 2A.

Figure 2C shows the measurement protocol with which the "instantaneous" I/V relationship was determined; the voltage was first stepped from a holding value of 0 mV to –70 mV, followed by steps to test values in the range of from +50 mV to –70 mV in 10 mV increments.

Figure 2D then shows the plot of the "instantaneous" I/V relationship measured at the time indicated by the arrow in Figure 2C (inset).

Figure 2E shows that the time course of the "tail" currents depends on the time at which the voltage is reset to + 30 mV.

Figure 2F shows the voltage dependence of the relative open probability, P_o, of the channel. The tail current amplitudes (arrow in part a) were normalized to the maximum current. The midpoint voltage, $V_{1/2}$, was -26.1 mV. The effective charge amount, Q, which is flowing during channel switching, is 3.5 elementary charges. It was achieved from a fit of the Boltzmann function to the data: Mean of 7 experiments.

Figure 3 indicates the modulation of SPIH channels by cyclic nucleotides.

Figure 3A shows the whole-cell SPIH current in the presence of 1 mM cAMP. The voltage-step protocol is the same as in Fig. 2A. The bath contained (mM): 135 NaCl, 5 KCl, 1.8 $CaCl_2$, 2.8 $MgCl_2$ and 5 Hepes-NaOH at pH 7.4; the pipette solution contained

(mM): 126 KCl, 10 Hepes-KOH, 10 EGTA at pH 7.4, and 1mM cAMP. The inset shows a magnification by way of which the sigmoidal time course can be seen particularly well.

Figure 3B shows the voltage dependence of the relative P_o, derived from normalized whole-cell tail currents at +10mV (●) and of tail currents recorded by inside-out patches (Δ). A continuous line represents a fit of the Boltzmann equation to the data. $V_{1/2}$ for the whole-cell currents of part A was –50.8mV and for the inside-out-patch currents of part E it was –84.7 mV; the Q values were 3.8 and 2.7, respectively.

Figure 3C shows the modulation of whole-cell SPIH currents by the photolysis of "caged" cAMP. The pipette solution contained 100 µM "caged" cAMP. The SPIH current was activated by voltage jumps from +10 mV to –70 mV before the UV flash was induced (trace 1) and after three consecutive UV flashes (trace 2). The time course of the flash-induced increase in current at –70 mV is shown below.

Figures 3D and E show voltage-activated SPIH currents in inside-out membrane patches without cAMP (D) and in the presence of 1 mM cAMP (E) in the bath. The voltage step protocol was carried out in the way as shown in Figure 2A. The pipettes and bath solutions contained (mM): 126 KCl, 10 Hepes-KOH, 10 EGTA at pH 7.4 and 1 mM cAMP (bath).

Figure 3F discloses the dependence of the SPIH current amplitude on the cAMP concentration; the cAMP concentrations were as follows (µM): 0.1; 0.3; 1; 3; 10 and 1000. A continuous line shows a fit of the Hill equation to the data; $K_{1/2}$ = 0.74 µM; n = 1.05; mean of 10 experiments.

Figure 4 shows several pharmacological properties of the SPIH channel.

Figures 4A and B show voltage-activated SPIH currents, recorded by outside-out membrane patches without (A) and with 10 mM Cs^+ (B) in the bath; the pipette solution contained the following (mM): 124 KCl, 10 Hepes-KOH, 10 EGTA at pH 7.4 and 1 mM cAMP; the bath solution contained (mM): 126 KCl, 10 Hepes-KOH, 10 EGTA at pH 7.4 and the illustrated concentrations of CsCl.

Figure 4C shows again the I/V relationship in the presence of 0 to 10 mM Cs^+ in the bath.

Figure 4D discloses the dependence of the normalized current at –70 mV on $[Cs^+]$. The continuous line shows a fit of the Hill equation to said data; K_i = 245 μM, Hill coefficient 1.2 (mean of 1-6 experiments).

Figure 4E shows the ion selectivity of the SPIH channel. V_{rev} was determined on inside-out patches by stepping the holding voltage (-70 mV) to test values between –30 mV and + 30 mV in 5 mV increments. The pipette solution contained the following (mM): 150 KCl, 10 Hepes-NMDG, 10 EGTA at pH 7.4; the bath solution was composed as follows (mM): 50 KCl, 100 XCl, 10 Hepes-NMDG, 10 EGTA at pH 7.4 and 0.1 cAMP.

Figure 4F shows the I/V relationship of the currents shown in part E. V_{rev} was 16.9 mV (Na^+), 20.6 mV (Li^+), 5.6 mV (Rb^+), and 24.6 mV (Cs^+); mean of 3 to 10 experiments. The relative ion permeabilities P_X/P_K were calculated according to the equation $P_X/P_K = \{[K^+]_o - [K^+]_i \exp(zFV_{rev}/RT)\} / [X^+]_i \exp(zFV_{rev}/RT)$.

Figure 4G shows the K^+ dependence of whole-cell inward Na^+ currents in the presence of 0.5 mM and 20 mM K^+ in extracellular medium.

Figure 4H shows the "instantaneous" I/V relationship in the presence of 0, 1, 3, 5, 10, and 20 mM K^+ in the bath.

The pipette solution was the same as in part B, the bath solution as in Figure 1A with the indicated K^+ concentrations; the ion intensities were adjusted to the same value by the respective NMDG concentrations.

Figure 5 shows the expression pattern of SPIH.

Figure 5A is a Northern Blot analysis of the tissue distribution of SPIH transcripts in mRNA of male gonads (lane 1), female gonads (lane 2) and intestinal cells (lane 3); 10 µl poly(A)$^+$RNA each.

Figure 5B is a Western Blot analysis of membranes of mock-transfected HEK293 cells (lane 1; 2.5 µg protein), HEK293 cells which were transfected with SPIH cDNA (lane 2; 2.5 µg protein), purified flagella from sperm of *S. purpuratus* (lane 3; 6 µg protein), dephosphorylated flagellar membranes (lane 4; 6 µg protein) and sperm heads (lane 5; 15 µg protein).

Reference table of the DNA sequences described in the text by SEQ ID numbers

SEQ ID NO	DNA sequence
1	Partial sequence of the I_h channel from human thalamus tissue
2	partial sequence of an I_h channel from olfactory rat tissue
3	partial sequence of an I_h channel from retinal bovine tissue
4	complete sequence of the I_h channel from sea urchin sperm
5	complete sequence of the I_h channel from *Drosophila melanogaster*
6	partial sequence of an I_h channel from retinal bovine tissue
7	partial sequence of an I_h channel from retinal bovine tissue
8	partial sequence of an I_h channel from olfactory rat tissue
9	partial sequence of an I_h channel from olfactory rat tissue
10	partial sequence of an I_h channel from human thalamus tissue
11	partial sequence of an I_h channel from human heart tissue
12	complete sequence of an I_h channel from retinal bovine tissue
13	partial sequence of an I_h channel from olfactory rat tissue
14	partial sequence of an I_h channel from olfactory rat tissue
15	complete sequence of an I_h channel from human heart tissue

Literature

Accili, E.A., Redaelli, G. and DiFrancesco, D.: Differential control of the hyperpolarization-activated current (i) by cAMP gating and phosphatase inhibition in rabbit sino-atrial node myocytes. J.Physiol. 500 (1997) 643-651.

Adams, S.R. and Tsien, R.Y.: Controlling cell chemistry with caged compounds. Annu.Rev.Physiol. 55 (1993) 755-784.

Aiba, H., Fujimoto, S. and Ozaki, N.: Molecular cloning and nucleotide sequencing of the gene for *E. coli* cAMP receptor protein. Nucleic Acids Res. 10 (1982) 1345-1361.

Altenhofen, W., Ludwig, J., Eismann, E., Kraus, W., Bönigk, W. and Kaupp, U.B.: Control of ligand specificity in cyclic nucleotide-gated channels from rod photoreceptors and olfactory epithelium. Proc.Natl.Acad.Sci.USA 88 (1991) 9868-9872.

Anderson, J.A., Huprikar, S.S., Kochian, L.V., Lucas, W.J. and Gaber, R.F.: Functional expression of a probable *Arabidopsis thaliana* potassium channel in *Saccharomyces cerevisiae*. Proc.Natl.Acad.Sci.USA 89 (1992) 3736-3740.

Araki, T., Ito, M. and Oshima, T.: Potential changes produced by application of current steps in motoneurones. Nature 191 (1962) 1104-1105.

Attwell, D. and Wilson, M.: Behavior of the rod network in the tiger salamander retina mediated by membrane properties of individual rods. J.Physiol. 309 (1980) 287-315.

Babcock, D.F., Bosma, M.M., Battaglia, D.E. and Darszon, A.: Early persistent activation of sperm K channels by the egg peptide speract. Proc.Natl.Acad.Sci.USA 89 (1992) 6001-6005.

Bader, C.R., MacLeish, P.R. and Schwartz, E.A.: A voltage-clamp study of the light response in solitary rods of the tiger salamander. J.Physiol. 296 (1979) 1-26.

Bader, C.R., Bertrand, D. and Schwartz, E.A.: Voltage-activated and calcium-activated currents studied in solitary rod inner segments from the salamander retina. J.Physiol. 331 (1982) 253-284.

Baumann, A., Frings, S., Godde, M., Seifert, R. and Kaupp, U.B.: Primary structure and functional expression of a *Drosophila* cyclic nucleotide-gated channel present in eyes and antennae. EMBO J. 13 (1994) 5040-5050.

Beltrán, C., Zapata, O. and Darszon, A.: Membrane potential regulates sea urchin sperm adenylylcyclase. Biochemistry 35 (1996) 7591-7598.

Brown, H.F. and DiFrancesco, D.: Voltage clamp investigations of current underlying pacemaker activity in rabbit-sino-atrial note. J. Physiol. 308 (1980) 221-251.

Brown, H.F., DiFrancesco, D. and Noble, S.J.: How does adrenaline accelerate the heart? Nature 280 (1979) 235-236.

Darszon, A., Labarca, P., Beltrán, C., García-Soto, J. and Liévano, A.: Sea urchin sperm: An ion channel reconstitution study case. Methods: A Companion to Methods in Enzymology 6 (1994) 37-50.

Darszon, A., Liévano, A. and Beltrán, C.: Ion channels: Key elements in gamete signaling. In Current Topics in Developmental Biology, Vol. 44. Academic Press, San Diego, 1996, pp.117-167.

Dayhoff, M.O., Schwartz, R. M., Orcutt, B.C. (1978) in: Atlas of protein sequence and structure, Band 5, Suppl. 3, Hrsg.: Dayhoff, M.O., National Biomedical Research Foundation, Silver Spring, MD, S. 345-352.

DiFrancesco, D.: A new interpretation of the pace-maker current in calf Purkinje fibres. J. Physiol. 314 (1981a) 359-376.

DiFrancesco, D.: A study of the ionic nature of the pace-maker current in calf Purkinje fibres. J. Physiol. 314 (1981b) 277-293.

DiFrancesco, D.: The hyperpolarization-activated current, i_f, and cardiac pacemaking. In Rosen, M.R., Janse, M.J. and Wit, A.L. (Eds.), Cardiac Electrophysiology: a Textbook. Futura, New York, 1990, pp.117-132.

DiFrancesco, D.: Pacemaker mechanisms in cardiac tissue. Annu.Rev.Physiol. 55 (1993) 455-472.

DiFrancesco, D. and Tortora, P.: Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 351 (1991) 145-147.

Fain, G.L., Quandt, F.N., Bastian, B.L. and Gerschenfeld, H.M.: Contribution of a caesium-sensitive conductance increase to the rod photoresponse. Nature 272 (1978) 467-469.

Finn, J.T., Grunwald, M.E. and Yau, K.-W.: Cyclic nucleotide-gated ion channels: An extended family with diverse functions. Annu.Rev.Physiol. 58 (1996) 395-426.

Garbers, D.L.: Molecular basis of fertilization. Annu.Rev.Biochem. 58 (1989) 719-742.

Garbers, D.L.: Guanylyl cyclase receptors and their endocrine, paracrine, and autocrine ligands. Cell 71 (1992) 1-4.

Hagen, V., Dzeja, C., Frings, S., Bendig, J., Krause, E. and Kaupp, U.B.: Caged compounds of hydrolysis-resistant analogues of cAMP and cGMP: Synthesis and application to cyclic nucleotide-gated channels. Biochemistry 35 (1996) 7762-7771.

Halliwell, J.V. and Adams, P.R.: Voltage-clamp analysis of muscarinic excitation in hippocampal neurons. Brain Res. 250 (1982) 71-92.

Hansbrough, J.R., Kopf, G.S. and Garbers, D.L.: The stimulation of sperm metabolism by a factor associated with eggs and by 8-bromo-guanosine 3',5'-monophosphate. Biochim.Biophys.Acta 630 (1980) 82-91.

Hille, B.: Ionic channels of excitable membranes. Sinauer Associates Inc., Sunderland, 1992.

Hodgkin, A.L. and Huxley, A.F.: A quantitative description of membrane current and its application to conduction and excitation in nerve. J.Physiol. 117 (1952) 500-544.

Ingram, S.L. and Williams, J.T.: Modulation of the hyperpolarization-activated current (I) by cyclic nucleotides in guinea-pig primary afferent neurons. J.Physiol. 492 (1996) 97-106.

Ito, M. and Oshima, T.: Electrical behavior of the motoneurone membrane during intracellularly applied current steps. J. Physiol. 180 (1965) 607-635.

Kaupp, U.B., Niidome, T., Tanabe, T., Terada, S., Bönigk, W., Stühmer, W., Cook, N.J., Kangawa, K., Matsuo, H., Hirose, T., Miyata, T. and Numa, S.: Primary structure and functional expression from complementary DNA of the rod photoreceptor cyclic GMP-gated channel. Nature 342 (1989) 762-766.

Labarca, P., Santi, C., Zapata, O., Morales, E., Beltrán, C., Liévano, A. and Darszon, A.: A cAMP regulated K-selective channel from the sea urchin sperm plasma membrane. Develop.Biol. 174 (1996) 271-280.

Lee, H.C. and Garbers, D.L.: Modulation of the voltage-sensitive Na/H exchange in sea urchin spermatozoa through membrane potential changes induced by the egg peptide speract. J.Biol.Chem. 261 (1986) 16026-16032.

Llinás, R.R.: The intrinsic electrophysiological properties of mammalian neurons; insights into central nervours system function. Science 242 (1988) 1654-1664.

Ludwig, J., Margalit, T., Eismann, E., Lancet, D. and Kaupp, U.B.: Primary structure of cAMP-gated channel from bovine olfactory epithelium. FEBS Lett. 270 (1990) 24-29.

Pape, H.-C.: Queer current and pacemaker: The hyperpolarization-activated cation current in neurons. Annu.Rev.Physiol. 58 (1996) 299-327.

Pongs, O., Kecskemethy, N., Müller, R., Krah-Jentgens, I., Baumann, A., Kiltz, H.H., Canal, I., Llamazares, S. and Ferrus, A.: *Shaker* encodes a family of putative potassium channel proteins in the nervous system of *Drosophila*. EMBO J. 7 (1988) 1087-1096.

Sanger, F., Nicklen, S. and Coulson, A.R.: DNA sequencing with chain-terminating inhibitors. Proc.Natl.Acad.Sci.USA 74 (1977) 5463-5467.

Smith, P.L., Baukrowitz, T. and Yellen, G.: The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379 (1996) 833-836.

Suarez, S.S., Varosi, S.M. and Dai, X.: Intracellular calcium increases with hyperactivation in intact, moving hamster sperm and oscillates with the flagellar beat cycle. Proc.Natl.Acad.Sci.USA 90 (1993) 4660-4664.

Takio, K., Wade, R.D., Smith, S.B., Krebs, E.G., Walsh, K.A. and Titani, K.: Guanosine cyclic 3',5'-phosphate dependent protein kinase, a chimeric protein homologous with two separate protein families. Biochemistry 23 (1984) 4207-4218.

Titani, K., Sasagawa, T., Ericsson, L.H., Kumar, S., Smith, S.B., Krebs, E.G. and Walsh, K.A.: Amino acid sequence of the regulatory subunit of bovine type I adenosine cyclic 3',5'-phosphate dependent protein kinase. Biochemistry 23 (1984) 4193-4199.

Trudeau, M.C., Warmke, J.W., Ganetzky, B. and Robertson, G.A.: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269 (1995) 92-95.

Varnum, M.D., Black, K.D. and Zagotta, W.N.: Molecular mechanism for ligand discrimination of cyclic nucleotide-gated channels. Neuron 15 (1995) 619-625.

Warmke, J., Drysdale, R. and Ganetzky, B.: A distinct potassium channel polypeptide encoded by the *Drosophila eag* locus. Science 252 (1991) 1560-1562.

Warmke, J.W. and Ganetzky, B.: A family of potassium channel genes related to *eag* in *Drosophila* and mammals. Proc.Natl.Acad.Sci.USA 91 (1994) 3438-3442.

Weiner, J.: Molekularbiologische, immunologische und funktionelle Charakterisierung von β-Untereinheiten des zyklisch Nukleotid-gesteuerten Ionenkanals aus dem Rinderhoden. Dissertation (1996) Universität Düsseldorf

Wollmuth, L.P. and Hille, B.: Ionic selectivity of I_h channels of rod photoreceptors in tiger salamanders. J.Gen.Physiol. 100 (1992) 749-765.

Yanagihara, K. and Irisawa, H.: Inward current activated during hyperpolarization in the rabbit sino atrial node cell. Pflügers Arch. 385 (1980) 11-19.

WHAT IS CLAIMED IS:

1. An isolated or purified nucleic acid which codes for an I_h ion channel or a part thereof, or a nucleic acid complementary thereto, except for the nucleic acids with the sequences indicated in the GenBank database under the accession number AF028737 and in the ENHUM database under the accession number N72770, wherein said nucleic acid is DNA or RNA.

2. The isolated or purified nucleic acid of claim 1, characterized in that the nucleic acid is of human origin.

3. The isolated or purified nucleic acid of claim 2, characterized in that the nucleic acid comprises the sequence according to SEQ ID NO 1 or a part thereof.

4. The isolated or purified nucleic acid of claim 1, characterized in that the nucleic acid is of rat origin.

5. The isolated or purified nucleic acid of claim 4, characterized in that the nucleic acid comprises the sequence according to SEQ ID NO 2 or a part thereof.

6. The isolated or purified nucleic acid of claim 1, characterized in that the nucleic acid is of bovine origin.

7. The isolated or purified nucleic acid of claim 6, characterized in that the nucleic acid comprises a sequence according to SEQ ID NO 3 or SEQ ID NO 12 or a part of either of the foregoing sequences.

8. The isolated or purified nucleic acid of claim 1, characterized in that the nucleic acid is of sea urchin origin.

9. The isolated or purified nucleic acid of claim 8, characterized in that the nucleic acid comprises the sequence according to SEQ ID NO 4 or a part thereof.

10. The isolated or purified nucleic acid of claim 1, characterized in that the nucleic acid is of *Drosophila* origin.

11. The isolated or purified nucleic acid of claim 10, characterized in that the nucleic acid comprises the sequence according to SEQ ID NO 5 or a part thereof.

12. An isolated or purified nucleic acid characterized in that the sequence thereof is at least 80% identical to the isolated or purified nucleic acid of SEQ ID NO 1, 2, 3, 4 or 12.

13. The isolated or purified nucleic acid of claim 12, characterized in that the sequence thereof is at least 90% identical to the isolated or purified nucleic acid of SEQ ID NO 1, 2, 3, 4 or 12.

14. An isolated or purified nucleic acid characterized in that the nucleic acid hybridizes under low stringency conditions with SEQ ID NO 1, 2, 3, 4, 5 and/or 12.

15. The isolated or purified nucleic acid of claim 14, characterized in that the nucleic acid hybridizes under stringent conditions with SEQ ID NO 1, 2, 3, 4, 5 and/or 12.

16. A vector comprising the isolated or purified nucleic acid of claim 1.

17. A host cell comprising the vector of claim 16.

18 A composition comprising the isolated or purified nucleic acid of claim 1 and a carrier therefor.

19. An isolated or purified polypeptide encoded by a nucleic acid of claim 1.

20. An isolated or purified polypeptide encoded by a nucleic acid of claim 3.

21. An isolated or purified polypeptide encoded by a nucleic acid of claim 5.

22. An isolated or purified polypeptide encoded by a nucleic acid of claim 7.

23. An isolated or purified polypeptide encoded by a nucleic acid of claim 9.

24. An isolated or purified polypeptide encoded by a nucleic acid of claim 11.

25. An isolated or purified polypeptide encoded by a nucleic acid of claim 12.

26. An isolated or purified polypeptide encoded by a nucleic acid of claim 13.

27. An isolated or purified polypeptide encoded by a nucleic acid of claim 14.

28. An isolated or purified polypeptide encoded by a nucleic acid of claim 15.

29. A composition comprising the isolated or purified polypeptide of claim 19 and a carrier therefor.

30. A monoclonal antibody that specifically binds to the polypeptide of claim 19.

31. A method of screening a substance for the ability to influence the activity of an I_h ion channel, which method comprises:

(a) providing a homogeneous I_h ion channel preparation,

(b) contacting the homogeneous I_h ion channel preparation with the substance,

(c) measuring the activity of the I_h ion channel preparation in the presence of the substance, and

(d) comparing the activity of the I_h ion channel preparation in the presence of the substance with the activity of the I_h ion channel preparation in the absence of the substance, wherein a change in the activity of the I_h ion channel preparation in the presence of the substance as compared to the activity of the I_h ion channel preparation in the absence of the substance indicates that the substance can influence the I_h ion channel.

32. The method of claim 31, wherein said I_h ion channel preparation is prepared by expressing the isolated or purified nucleic acid which codes for an I_h ion channel or a part thereof, or a nucleic acid complementary thereto, except for the nucleic acids with the sequences indicated in the GenBank database under the accession number AF028737 and in the ENHUM database under the accession number N72770, wherein said nucleic acid is DNA or RNA, in a host cell.

33. The method of claim 31, wherein said I_h ion channel preparation consists essentially of the polypeptide encoded by the isolated or purified nucleic acid which codes for an I_h ion channel or a part thereof, or a nucleic acid complementary thereto, except for the

nucleic acids with the sequences indicated in the GenBank database under the accession number AF028737 and in the ENHUM database under the accession number N72770.

34. A method of diagnosing an I_h ion channel-associated disorder in a patient, which method comprises:

(a) contacting a nucleic acid sample from said patient with a detectably labeled isolated or purified nucleic acid of claim 1 under hybridizing conditions,

(b) detecting the label of the detectably labeled isolated or purified nucleic acid molecule, and

(c) comparing the level of detection of the label in (b) with the level of detection of the label in a control sample, wherein a difference in the level of detection of the label in (b) and the level of detection of the label in a control sample is indicative of an I_h ion channel-associated disorder in a patient.

35. The method of claim 34, wherein the detectably labeled isolated and purified nucleic acid is mutated, in which case the detection of the label in (b) is indicative of the presence of a nucleic acid encoding a mutated I_h ion channel in the nucleic acid sample of the patient.

36. The method of claim 34, wherein said I_h ion channel-associated disorder is a cardiovascular disorder.

37. A method of prophylactically or therapeutically treating a mammal for a cardiovascular disorder, which method comprises administering to said mammal a vector comprising and expressing a prophylactically or therapeutically effective amount of an isolated or purified nucleic acid of claim 1, whereupon said mammal is treated for said cardiovascular disorder.

38. The method of claim 37, wherein said cardiovascular disorder is due to a faulty control of the sinus node.

39. A method of prophylactically or therapeutically treating a mammal for a cardiovascular disorder, which method comprises administering to said mammal a prophylactically or therapeutically effective amount of a polypeptide of claim 19, whereupon said mammal is treated for said cardiovascular disorder.

40. The method of claim 39, wherein said cardiovascular disorder is due to a faulty control of the sinus node.

41. A method of prophylactically or therapeutically treating a mammal for a disturbance of consciousness, which method comprises administering to said mammal a vector comprising and expressing a prophylactically or therapeutically effective amount of an isolated or purified nucleic acid of claim 1, whereupon said mammal is treated for said disturbance of consciousness.

42. The method of claim 41, wherein said disturbance of consciousness is due to a malfunction in thalamic neurons.

43. A method of prophylactically or therapeutically treating a mammal for a disturbance of consciousness, which method comprises administering to said mammal a prophylactically or therapeutically effective amount of a polypeptide of claim 19, whereupon said mammal is treated for said disturbance of consciousness.

44. The method of claim 43, wherein said disturbance of consciousness is due to a malfunction in thalamic neurons.

45. A method of prophylactically or therapeutically treating a mammal for a pain state, which method comprises administering to said mammal a vector comprising and expressing a prophylactically or therapeutically effective amount of an isolated or purified nucleic acid of claim 1, whereupon said mammal is treated for said pain state.

46. A method of prophylactically or therapeutically treating a mammal for a pain state, which method comprises administering to said mammal a prophylactically or therapeutically effective amount of a polypeptide of claim 19, whereupon said mammal is treated for said pain state.

Abstract

Sequences of an I_h ion channel and use thereof

The present invention relates to a nucleic acid, preferably a DNA, comprising at least a part of the sequence of an I_h ion channel. Said sequence may e.g. be derived from a human DNA, a rat DNA, a bovine DNA, a *Drosophila melanogaster* DNA or a sea urchin DNA. Furthermore, the present invention relates to an mRNA molecule which contains the corresponding sequences. The invention further relates to a polypeptide or protein encoded by the nucleic acid.

Furthermore, the invention relates to the use of the inventive nucleic acid and proteins for a screening and/or diagnosing method and to the kits required therefor.

Lastly, the invention relates to the use of one or more nucleic acids and proteins for the treatment and/or prophylaxis of cardiovascular disorders and disturbances of consciousness.

Fig. 1A

Sequence ID No. 4

```
CGGGAGAATAGTGCACCAAGGGATGCCCGTGAAATATTAATTAAACGTTTTTAAGAACA   -101
TCATCAAACCCGGGCCCCATCATGAAGGAATAACAAGGCCTTCGAAAAGTATGGGAAACT   -41
GGTCGGCAGGACATCAGCATTATTAATTCTAGGAAACTCATTATGGATAACAAGGAAACT    18
                                            M  D  N  K  E  T     6

AACGGAGAGCTAGAGCAGTCTGATGAGGCCGATCCGTCCGGTCAAAACCTTGATGATGGG    78
 N  G  E  L  E  Q  S  D  E  A  D  P  S  G  Q  N  L  D  D  G     26

GAAACCGATAGCAAACAAGAAGAGAATCTCATCAACGTTAGCCCGCCAAAAACACCGCCA   138
 E  T  D  S  K  Q  E  E  N  L  I  N  V  S  P  P  K  T  P  P     46

GGTCCTCCTCCTCCTCTAAAGAATGGAGGAAGGGGTCAGAAACCGCCCAAAATCCCAATA   198
 G  P  P  P  P  L  K  N  G  G  R  G  Q  K  P  P  K  I  P  I     66

TGTCATCAAAATGGAAAGCTCCCCAAGGAAGTTGAATGGACAGAAGACAGAGGCGAAGAC   258
 C  H  Q  N  G  K  L  P  K  E  V  E  W  T  E  D  R  G  E  D     86

AGAAAGGATAGTCTCACTCTTCAATCAAAGCTAGATCACGGGGCATACACGGATGAGAAA   318
 R  K  D  S  L  T  L  Q  S  K  L  D  H  G  A  Y  T  D  E  K    106
          ▲
CAGGATCTTCTAACATATCTTGACCGTCACGGCATCAACAGTCCAGTCAAGCTAACACCA   378
 Q  D  L  L  T  Y  L  D  R  H  G  I  N  S  P  V  K  L  T  P    126

GATGAAACTGGAGGGAGCAGTGCTTTGGATATTCTTGGGATTATTGAAGAGAGGGACACT   438
 D  E  T  G  G  S  S  A  L  D  I  L  G  I  I  E  E  R  D  T    146

GGTGCACTAGGCTCTGATCCCTCATCCACTATGCAGGCCATGGCTAAACCTGTAGGCTTT   498
 G  A  L  G  S  D  P  S  S  T  M  Q  A  M  A  K  P  V  G  F    166

CTGCAGAGGCAGCTATGGACTGTCCTCCAACCTTCAGACAATAGACTCTCCATGAAACTT   558
 L  Q  R  Q  L  W  T  V  L  Q  P  S  D  N  R  L  S  M  K  L    186
                                                 •
TTCGGAAGCAAGAAAGGGTTACAAAAGGAAAAATATCGGCTGAGGAAGGCGGGGGTTCTT   618
 F  G  S  K  K  G  L  Q  K  E  K  Y  R  L  R  K  A  G  V  L    206
       •
                            ------------------------- S1 -------
ATCATTCATCCATGTAGTCATTTCAGATTTTACTGGGATCTACTGATGCTGTGCCTGATC   678
 I  I  H  P  C  S  H  F  R  F  Y  W  D  L  L  M  L  C  L  I    226
------------------------------
ATGGCAAACGTCATCCTCCTACCCGTCGTCATTACTTTCTTCCACAACAAGGACATGAGT   738
 M  A  N  V  I  L  L  P  V  V  I  T  F  F  H  N  K  D  M  S    246
      ---------------------------------------- S2 ---------
ACGGGTTGGCTCATCTTTAATTGCTTCTCAGATACCTTCTTCATTCTCGATCTCATCTGC   798
 T  G  W  L  I  F  N  C  F  S  D  T  F  F  I  L  D  L  I  C    266
--
AACTTTCGGACCGGCATCATGAATCCGAAGTCGGCCGAACAGGTGATCCTCAACCCCCGT   858
 N  F  R  T  G  I  M  N  P  K  S  A  E  Q  V  I  L  N  P  R    286
                                ---------------------- S3 ------
CAAATCGCCTATCATTATCTCCGTTCATGGTTCATCATCGATCTCGTGTCTTCCATCCCC   918
 Q  I  A  Y  H  Y  L  R  S  W  F  I  I  D  L  V  S  S  I  P    306
```

ATGGACTACATCTTCCTCCTCGCTGGCGGCCAGAACCGTCACTTCCTCGAGGTGTCCCGA 978
M D Y I F L L A G G Q N R H F L E V S R 326

S4

GCCCTCAAGATACTGCGCTTTGCCAAGCTCCTCAGTCTTCTTCGACTCCTGCGTCTGTCC 1038
A L K I L R F A K L L S L L R L L R L S 346

AGGCTCATGCGGTTCGTCAGTCAATGGGAACAGGCCTTCAACGTAGCCAATGCCGTCATC 1098
R L M R F V S Q W E Q A F N V A N A V I 366

S5

CGGATCTGTAATCTAGTGTGTATGATGCTTCTGATTGGCCATTGGAATGGCTGCCTTCAA 1158
R I C N L V C M M L L I G H W N G C L Q 386

TATCTCGTGCCCATGCTGCAAGAATACCCCGACCAATCATGGGTCGCCATTAATGGCCTT 1218
Y L V P M L Q E Y P D Q S W V A I N G L 406

Pore

GAGCACGCTCATTGGTGGGAGCAGTATACATGGGCACTCTTCAAAGCCCTTTCGCACATG 1278
E H A H W W E Q Y T W A L F K A L S H M 426

CTCTGTATCGGGTACGGCAAGTTCCCCCCTCAAAGCATCACCGATGTCTGGCTAACGATT 1338
L C I G Y G K F P P Q S I T D V W L T I 446

S6

GTCAGTATGGTGTCCGGTGCGACCTGCTTCGCCCTGTTCATCGGACACGCTACCAATCTC 1398
V S M V S G A T C F A L F I G H A T N L 466

ATCCAGTCCATGGACTCCTCCAGCAGGCAATACCGTGAGAAGTTGAAACAAGTTGAAGAG 1458
I Q S M D S S S R Q Y R E K L K Q V E E 486

TACATGCAGTATCGCAAGCTACCGTCCCACCTACGAAACAAGATCCTCGATTACTACGAG 1518
Y M Q Y R K L P S H L R N K I L D Y Y E 506

TACCGATACCGAGGAAAGATGTTTGATGAGAGGCATATCTTTCGAGAAGTGTCGGAGAGT 1578
Y R Y R G K M F D E R H I F R E V S E S 526

ATACGACAGGATGTCGCAAACTACAATTGTCGCGACCTGGTCGCATCCGTCCCTTTCTTC 1638
I R Q D V A N Y N C R D L V A S V P F F 546

GTCGGTGCCGACTCAAACTTCGTCACCCGTGTGGTGACGCTGCTCGAATTCGAGGTCTTC 1698
V G A D S N F V T R V V T L L E F E V F 566

CAACCCGCTGACTATGTTATACAGGAAGGTACTTTCGGTGATCGCATGTTCTTCATCCAG 1758
Q P A D Y V I Q E G T F G D R M F F I Q 586

CAGGGCATCGTCGACATCATCATGTCCGACGGCGTCATCGCCACGTCACTCAGTGACGGC 1818
Q G I V D I I M S D G V I A T S L S D G 606

cNMP binding site

TCATATTTTGGCGAAATCTGCCTGCTTACCCGTGAGCGCCGCGTGGCATCGGTGAAGTGC 1878
S Y F G E I C L L T R E R R V A S V K C 626

GAGACCTACTGCACGCTCTTCTCGCTCTCCGTCCAGCATTTCAACCAAGTGCTCGACGAG 1938
E T Y C T L F S L S V Q H F N Q V L D E 646

```
TTTCCCGCCATGAGGAAAACGATGGAAGAGATAGCCGTTCGTCGTCTGACCCGAATCGGG  1998
 F  P  A  M  R  K  T  M  E  E  I  A  V  R  R  L  T  R  I  G    666
                                                 ▲
AAGGAATCGAGCAAGCTGAAATCCCGCCTAGAGAGCCCGACGATCAGGGACACTGCCCCT  2058
 K  E  S  S  K  L  K  S  R  L  E  S  P  T  I  R  D  T  A  P    686
       •                                 •
CTCTTTCCGATCCCACCTGATACACCGTCTTTCGTCACCGACATCGAAAAGAACCGGTTC  2118
 L  F  P  I  P  P  D  T  P  S  F  V  T  D  I  E  K  N  R  F    706

TTTGGCGACGACACGGACGATGTACACATCAGGACCCGAGTCGACGTCGAGCGTGGTTCG  2173
 F  G  D  D  T  D  D  V  H  I  R  T  R  V  D  V  E  R  G  S    726

CATGAAAACGTCATCGCCATCATGGATGGGAGTTTATCCGACCTCAGGATGGAAAACGAA  2238
 H  E  N  V  I  A  I  M  D  G  S  L  S  D  L  R  M  E  N  E    746

ATCCAAGCCCGTAAATCGTCTAGCGGAAAACGGAGGAAATTCCAGCAACAAACAACCGAA  2298
 I  Q  A  R  K  S  S  S  G  K  R  R  K  F  Q  Q  Q  T  T  E    766
                    ▲  •
CTATGACGACTTGAAACAAACAATGATGGACGCTTACAATTTCCAGTGATTCAATACTTA  2358
 L  -                                                           767

CGCAATGCAGACATTAGCTTTTGTACCTGATTGTTTAGAATGTATTGAATTTGTAGATCA  2413
GTCCGGCAAATAAGAAAGCATAATTTGGAATTTCTTTCATTGAGGAAGTACTGAAAACAA  2478
TGTGATAGCAGCCGGTAGAAATTTCTTGTCCATTATCGAGGCTATATTTTTCGCGCTTTC  2538
TTACGAAGTAAATGAAAGGATCAATTAAATTATTGTTCTTTGTCTCGTGCGCTTTGTATC  2598
TGATGCCGAAAAGGAATGAAACGTGATTAGAACAGTAATCGATTGAACTACAGAAGTCTT  2658
TTCAAAATGTTGAATGTATGAAGGAGGAGGGGAAGGTTTGATATATGCAAAGAAATGGA   2718
GAAATATTTTTGTAAATTTATCTAGAATGGTACTATTGATGCTGGAAAGGTGTTGAAGTT  2778
GTCCAATATTGTGTCAAATCACCAACTATTTGACATTTGTCTTTTTC               2825
```

Fig. 1B, 1C

B

S4 motif



C

pore



cNMP binding domain

Fig. 1D



Fig. 2A, 2B



Fig, 2C, 2D


C
0 mV
−70 mV
+50 mV
1nA
20ms
0.5 nA
500 ms
D
I_{tail} (nA)
1.2
0.8
0.4
−0.4
30
−30
−60
V_m (mV)

Fig, 2E, 2F



Fig. 3A, 3B



Fig. 3C, 3D


C
+10 mV
−70 mV
1
2
1 nA
300 ms
−70 mV
UV
1 nA
2 sec


D
control
500 pA
500 ms

Fig. 3E, 3F

E



F



Fig. 4


A
0 Cs+
B
10 Cs+
0.5 nA
500 ms
C
Itail (pA)
800
400
-400
-800
-80
-40
40
Vm (mV)
10
1
0.3
0.1
0.03
0
[Cs+]o (mM)
D
I/Imax
0.8
0.4
0.0
[Cs+]o (mM)
10-4 10-3 10-2 10-1 100 101 102

Fig. 4E



Fig. 4F



Fig. 4G



Fig. 4H



Fig. 5



Fig. 6



SEQUENCE LISTING

<110> Forschungszentrum Jülich GmbH

<120> Sequences of an I_h ion channel and use thereof

<130> PCT981

<140> PCT/EP99/00942
<141> 1999-02-12

<150> DE 198 06 581.7
<151> 1998-02-17

<160> 18

<170> PatentIn Ver. 2.1

<210> 1
<211> 1342
<212> DNA
<213> Homo sapiens

<400> 1
cgttgcgctt caccaagatc ctcagcctcc tgcggctgct gcgcctctca cgcctgatcc 60
gctacatcca tcagtgggag gagatcttcc acatgaccta tgacctggcc agcgcggtga 120
tgaggatctg caatctcatc agcatgatgc tgctgctctg ccactgggac ggctgcctgc 180
agttcctggt gcccatgctg caggacttcc cgcgcaactg ctgggtgtcc atcaatggca 240
tggtgaacca ctcgtggagt gaactgtact ccttcgcact cttcaaggcc atgagccaca 300
tgctgtgcat cgggtacggc cggcaggcgc ccgagagcat gacggacatc tggctgacca 360
tgctcagcat gattgtgggt gccacctgct acgccatgtt catcggccac gccactgccc 420
tcatccagtc gctggactcc tcgcggcgcc agtaccagga gaagtacaag caggtggagc 480
agtacatgtc cttccacaag ctgccagctg acttccgcca gaagatccac gactactatg 540
agcaccgtta ccagggcaag atgtttgacg aggacagcat cctgggcgag ctcaacgggc 600
ccctgcggga ggagatcgtc aacttcaact gccggaagct ggtggcctcc atgccgctgt 660
tcgccaacgc cgaccccaac ttcgtcacgg ccatgctgac caagctcaag ttcgaggtct 720
tccagccggg tgactacatc atccgcgaag gcaccatcgg gaagaagatg tacttcatcc 780
agcacggcgt ggtcagcgtg ctcactaagg gcaacaagga gatgaagctg tccgatggct 840
cctacttcgg ggagatctgc ctgctcaccc ggggccgccg cacggcgagc gtgcgggctg 900
acacctactg ccgcctctat tcgctgagcg tggacaactt caacgaggtg ctggaggagt 960
accccatgat gcggcgcgcc ttcgagacgg tggccatcga ccgcctggac cgcatcggca 1020
agaagaattc catcctcctg cacaaggtgc agcatgacct caactcgggc gtattcaaca 1080
accaggagaa cgccatcatc caggagatcg tcaagtacga ccgcgagatg gtgcagcagg 1140
ccgagctggg ctcagcgcgt gggcctcttc ccgccgccgc cgccgccgcc gcagtcacct 1200
cggccatcgc cacgctgcag caggcggcgg ccatgagctt ctgcccgcag tggcgcggcc 1260
gctcgtgggg ccgctggcgc tcggctcgcc gcgcctcgtg cgchgcyndy hcccggggsc 1320
cgcacctgch gccncctcac cc 1342

<210> 2
<211> 3112
<212> DNA
<213> Rattus rattus

<400> 2
cctggttcgt ggtggacttc atctcctcga tcccggtgga ttatatcttt cttattgtag 60
agaaaggaat ggattcggaa gtttacaaga ccgccagagc acttcggatc gtgaggttta 120
caaaaattct cagtctcttg cgtttattac gcctttcaag gttaattaga tacatacacc 180
agtgggaaga gatattccac atgacatatg atctcgccag tgcagtggtg agaatcttca 240
acctcattgg catgatgctg ctcctgtgtc actgggatgg ctgtcttcag tttctggtcc 300

```
ccctgctgca ggacttccca ccggattgct gggtttctct aaatgaaatg gttaatgatt 360
catgggggaa acagtattcc tacgcactct tcaaagctat gagtcacatg ctgtgcattg 420
gttatggcgc ccaggccccc gtcagcatgt ctgacctctg gattaccatg ctgagcatga 480
ttgttggggc cacctgctat gccatgtttg tcggccatgc cacagctttg atccagtctc 540
tggattcttc aaggaggcag tatcaagaga agtacaagca agtagagcaa tacatgtcat 600
tccacaagtt accagctgac atgcgccaga agatacatga ttactatgag caccgatacc 660
aaggcaagat cttcgatgag gaaaatattc tcagtgaact taatgatcct ctgagagagg 720
aaatagtcaa cttcaactgc cggaaactgg tggccaccat gcctctcttt gctaacgcgg 780
atcccaattt cgtgacggcc atgctgagca agctgagatt tgaggtgttc cagcccggag 840
actatatcat tcgagaagga gctgtgggga agaaaatgta tttcatccag catggtgtgg 900
ctggtgtcat caccaagtcc agtaaagaaa tgaagttgac agacggctct tactttggag 960
aaatatgcct gctgaccaag ggccggcgca ctgccagtgt tcgagctgat acatactgtc 1020
gcctttactc cctttcggtg gacaatttca acgaggtctt ggaggaatat ccaatgatga 1080
gaagagcctt tgagacagtt gctattgacc gactagatcg gataggcaag aaaaactcta 1140
ttctcctgca gaagttccag aaggatctga acactggtgt tttcaacaac caggagaatg 1200
agatcctgaa gcagattgtg aagcatgaca gagagatggt acaagcgatc cctccaatca 1260
actatcctca aatgacagcc ctgaattgca catcttcaac caccaccca acgtcgcgca 1320
tgaggaccca atctccacca gtctacacag cgaccagcct ctctcacagc aacctgcact 1380
cacccagccc cagcacacag acgcctcaac cctcagccat cctttcaccc tgctcctaca 1440
ccacagcagt ctgcagtcct cctatacaga gccccctggc cacgcgaact ttccattatg 1500
cctctcccac tgcatcccaa ttgtcactca tgcagcagcc tcagccgcag ctacagcaat 1560
cccaggtaca gcagactcag ccgcagccgc agccgcagcc gcagcagccg caacagcaac 1620
aacagcagca acagcagcag cagcagcagc agcaacaaca acagcagcag caacagccac 1680
agacacctgg tagttccaca ccgaaaaatg aagtgcacaa gagcactcaa gctcttcata 1740
acaccaacct gaccagagaa gtcaggcccc tctctgcctc gcagccttcg ctgccccatg 1800
aggtctccac tatgatctcc agaccgcatc ccactgtggg cgagtccctg gcctccatcc 1860
ctcaacccgt ggcaacagtc cacagcactg gccttcaggc agggagcagg agcaccgtgc 1920
cacagcgtgt caccttgttc agacagatgt cctcgggagc tatttccccc aaccgaggag 1980
tgcctccagc acccccacca ccagcagctg tgcagagaga gtctccctca gtcttaaata 2040
aagacccaga tgcagaaaaa ccacgttttg cttcgaattt atgattcttg ctgattgtca 2100
aagcagaaaa gaaatactct aataaacaga atattctcag atattatttt attctatctc 2160
atgatagagc cctatagcct actctaaaaa gatattttag aagctctggc gtacatgcaa 2220
atgtaaaaac atatatacat atattattaa atatatatat atatctaaat gcccaagaga 2280
agttcaaaag acttgtataa ctttcagtgt tatgtcttcc tttctttaaa accattaaag 2340
gatttaacac attgttgtaa gatcattgat ttctaacctt ttacttaatt cctttgttat 2400
atgtgtttct ccctttttatg aagagttctt gaagtcattg gaaacaaaac tctgatttag 2460
aaataaaagg caactccaat tagtttcagc atagcaccaa tcaaagcttt ctttcattaa 2520
ctgtgcctct gcatctaggt tgttaattat gtgggattca ataaagaaat cccagtttat 2580
agctctaaat tgtattttgg tgctttaaat tttgagttat gtgaaggaac acactacacg 2640
ctcagccacc ataggagact aacattgcca ctgttaaggc ttcctctaac ctcaaacatg 2700
ttcgtcaatt ttgtgaggaa aggtgaggag atatttgtct tcatgtgtta ttggactttt 2760
accaagattc agtcaatgtt agctgtaaat aacttttcca acctgaataa aagtaactat 2820
tctgtgttgt ataaaggtaa aagtcactgt ttaagaattt agttttattg cttcacttca 2880
aaagttagag ttttaaaatt tcacaaaaca taataattgt gacaactgtt caaatgtaat 2940
gcaattgctt gagacctaca atatcattta aacctgcaat attttatgca aaaattgtat 3000
gcttgaacct acaaattgct tgtattacac caaaaatcat tacttttatt ccttcttgac 3060
ataatcaagc atctgaacct agtcctggca tgcttttggg ggcaaaaaaa aa        3112
```

<210> 3
<211> 2606
<212> DNA
<213> Bos taurus

<400> 3

```
cgggagcccg gagcgcagcc actgagggca gcggcggcgg cgggagcgag gcgcgcagcg 60
agaagcggcg gcgaggaatc ggccgggggc ttcgaggacg ccgagggggcc ccggcggcag 120
tacggcttca tgcagcggca gttcacctcc atgctgcagc ccggggtcaa caaattctcc 180
ctccgcatgt tcgggagcca gaaggcggtg gagaaggagc aggaaagggt taaaactgca 240
ggcttctgga ttatccaccc ttacagtgat ttcaggtttt attgggattt aataatgctt 300
ataatgatgg ttggaaatct ggtcatcata ccagttggaa tcacattctt tacagaacag 360
```

acaacaacac catggattat tttcaatgtg gcttcagata cagttttcct tttggacttg 420
atcatgaatt tcaggactgg gactgtcaat gaagacagtt ctgaaatcat cctggaccct 480
aaagtgatca agatgaatta tttaaaaagc tggtttgtgg ttgacttcat ctcatcaatc 540
ccagtggatt atatctttct cattgtagaa aaaggaatgg attcggaagt ttacaagaca 600
gccagggcac ttcgcattgt gaggtttaca aaaattctca gtctcttgcg tttattacga 660
ctttcaaggt taattagata catacatcag tgggaagaga ttttccacat gacatatgat 720
cttgccagtg ctgtggtgag aatttttaac ctcattggca tgatgctgct cctgtgccac 780
tgggatggct gtcttcagtt cctggtacca ctgctgcagg acttcccacc agattgctgg 840
gtgtctctaa atgagatggt taatgattct tggggaaagc agtattccta cgcgctcttc 900
aaagcgatga gtcatatgct gtgcattggc tacggagccc aagcccccgt gagcatgtct 960
gacctgtgga tcaccatgct gagcatgatc gtcggggcca cctgctacgc catgtttgtt 1020
ggccacgcca cggctctaat tcagtctttg gattcctcaa ggcggcaata tcaagagaag 1080
tataagcaag tggaacaata catgtcattc cataagttac cagctgatat gcgtcagaag 1140
atacatgatt attatgaaca cagataccaa ggcaaaatct ttgatgagga aaatattctc 1200
aatgaactca atgatcctct gagagaggag atagtcaact tcaactgccg aaaactagtg 1260
gctacaatgc ctctttttgc taatgcggat cctaatttcg tgaccgccat gctgagcaag 1320
ttgagatttg aggtgtttca acctggagat tatatcatac gagaaggagc tgtggctaaa 1380
aaaatgtatt tcattcaaca tggtgttgct ggtgtcatca caaaatccag taaagaaatg 1440
aagctgacag atggctcata ctttggagag atttgcttgc tgaccaaggg acggcgcact 1500
gccagtgttc gagctgatac atattgtcgt ctttactcac tttctgtgga caatttcaat 1560
gaggtcctgg aggaatatcc aatgatgaga agagcctttg agacggttgc cattgaccga 1620
ttagatagga tagggaagaa aaattcaatt ctcctgcaaa agttccagaa ggatctgaac 1680
acgggtgttt tcaacaatca ggagaacgag atcctgaagc agattgtgaa acacgacagg 1740
gaaatggtgc aggcaatccc tcccctcaat taccctcaaa tgacagccct gaattccacc 1800
tcttcaacta ctaccccgac ctctcgcctg aggacacagt caccgccagt gtacacagcc 1860
accagtctgt ctcatagcaa cctgcactcc cccagcccca gcacccagac cccccagccg 1920
tcagccatcc tctcgccctg ctcctacacc accgctgtct gcagccctcc tgtacagagc 1980
ccgctagcca ctcgaacttt ccactatgcc tcccccacgg cttcccagtt gtccctcatt 2040
cagcagcagc aggttcagca gccaccgcag ccccagcagc caccccaacc tccacagacc 2100
cccggcagct ccacaccgaa aaacgaagtg cacaagagca cgcaggcgct tcacaacacc 2160
agcctgaccc gagaagtcag gcccctctcg gcctcgcagc cctcgctgcc ccacgaggtc 2220
tccaccctga tctccagacc gcatcccact gtgggcgagt ccctggcctc catccctcaa 2280
cccgtgacca cggtccacgg ctcgggcctg caggcagggg gcaggggcac cgtcccccag 2340
cgagtcaccc tgttccgaca gatgtcatcg ggagccatcc cccccaatcg aggagtcccc 2400
ccggcccccc ctccaccagc agccgctcat ccgagggagg cgccctcagt cttaactaca 2460
gactcagagg cagaaaagcc acgatttgct tcaaatttat gatcctgctg attgtaaagc 2520
agaaagaaat actctaacgt aactgaggac gcttctcaga tttgatttta ttctatctcc 2580
tgatagatcc tctagcctac tatgaa 2606

<210> 4
<211> 2986
<212> DNA
<213> Strongylocentrotus purpuratus

<400> 4
cgggagaata gtgcaccaag ggatgcccgt gaaatattaa ttaaacgttt ttaagaacat 60
catcaaaccc gggccccatc atgaaggaat aacaaggcct tcgaaaagta tgggaaactg 120
gtcggcagga catcagcatt attaattcta ggaaactcat tatggataac aaggaaacta 180
acggagagct agagcagtct gatgaggccg atccgtccgg tcaaaacctt gatgatgggg 240
aaaccgatag caaacaagaa gagaatctca tcaacgttag cccgccaaaa acaccgccag 300
gtcctcctcc tcctctaaag aatggaggaa ggggtcagaa accgcccaaa atcccaatat 360
gtcatcaaaa tggaaagctc cccaaggaag ttgaatggac agaagacaga ggcgaagaca 420
gaaaggatag tctcactctt caatcaaagc tagatcacgg ggcatacacg gatgagaaac 480
aggatcttct aacatatctt gaccgtcacg gcatcaacag tccagtcaag ctaacaccag 540
atgaaactgg agggagcagt gctttggata ttcttgggat tattgaagag agggacactg 600
gtgcactagg ctctgatccc tcatccacta tgcaggccat ggctaaacct gtaggctttc 660
tgcagaggca gctatggact gtcctccaac cttcagacaa tagactctcc atgaaacttt 720
tcggaagcaa gaaagggtta caaaaggaaa aatatcggct gaggaaggcg ggggttctta 780
tcattcatcc atgtagtcat ttcagatttt actgggatct actgatgctg tgcctgatca 840
tggcaaacgt catcctccta cccgtcgtca ttactttctt ccacaacaag gacatgagta 900

cggttggct catctttaat tgcttctcag ataccttctt cattctcgat ctcatctgca 960
actttcggac cggcatcatg aatccgaagt cggccgaaca ggtgatcctc aacccccgtc 1020
aaatcgccta tcattatctc cgttcatggt tcatcatcga tctcgtgtct tccatcccca 1080
tggactacat cttcctcctc gctggcggcc agaaccgtca cttcctcgag gtgtcccgag 1140
ccctcaagat actgcgcttt gccaagctcc tcagtcttct tcgactcctg cgtctgtcca 1200
ggctcatgcg gttcgtcagt caatgggaac aggccttcaa cgtagccaat gccgtcatcc 1260
ggatctgtaa tctagtgtgt atgatgcttc tgattggcca ttggaatggc tgccttcaat 1320
atctcgtgcc catgctgcaa gaataccccg accaatcatg ggtcgccatt aatggccttg 1380
agcacgctca ttggtgggag cagtatacat gggcactctt caaagccctt tcgcacatgc 1440
tctgtatcgg gtacggcaag ttccccccctc aaagcatcac cgatgtctgg ctaacgattg 1500
tcagtatggt gtccggtgcg acctgcttcg ccctgttcat cggacacgct accaatctca 1560
tccagtccat ggactcctcc agcaggcaat accgtgagaa gttgaaacaa gttgaagagt 1620
acatgcagta tcgcaagcta ccgtcccacc tacgaaacaa gatcctcgat tactacgagt 1680
accgataccg aggaaagatg tttgatgaga ggcatatctt tcgagaagtg tcggagagta 1740
tacgacagga tgtcgcaaac tacaattgtc gcgacctggt cgcatccgtc cctttcttcg 1800
tcggtgccga ctcaaacttc gtcacccgtg tggtgacgct gctcgaattc gaggtcttcc 1860
aacccgctga ctatgttata caggaaggta ctttcggtga tcgcatgttc ttcatccagc 1920
agggcatcgt cgacatcatc atgtccgacg gcgtcatcgc cacgtcactc agtgacggct 1980
catattttgg cgaaatctgc ctgcttaccc gtgagcgccg cgtggcatcg gtgaagtgcg 2040
agacctactg cacgctcttc tcgctctccg tccagcattt caaccaagtg ctcgacgagt 2100
ttcccgccat gaggaaaacg atggaagaga tagccgttcg tcgtctgacc cgaatcggga 2160
aggaatcgag caagctgaaa tcccgcctag agagcccgac gatcagggac actgcccctc 2220
tctttccgat cccacctgat acaccgtctt tcgtcaccga catcgaaaag aaccggttct 2280
ttggcgacga cacggacgat gtacacatca ggacccgagt cgacgtcgag cgtggttcgc 2340
atgaaaacgt catcgccatc atggatggga gtttatccga cctcaggatg gaaaacgaaa 2400
tccaagcccg taaatcgtct agcggaaaac ggaggaaatt ccagcaacaa acaaccgaac 2460
tatgacgact tgaaacaaac aatgatggac gcttacaatt tccagtgatt caatacttac 2520
gcaatgcaga cattagcttt tgtacctgat tgtttagaat gtattgaatt tgtagatcag 2580
tccggcaaat aagaaagcat aatttggaat ttctttcatt gaggaagtac tgaaaacaat 2640
gtgatagcag ccggtagaaa tttcttgtcc attatcgagg ctatattttt cgcgctttct 2700
tacgaagtaa atgaaaggat caattaaatt attgttcttt gtctcgtgcg ctttgtatct 2760
gatgccgaaa aggaatgaaa cgtgattaga acagtaatcg attgaactac agaagtcttt 2820
tcaaaatgtt gaatgtatga aggaggaggg ggaaggtttg atatatgcaa agaaatggag 2880
aaatattttt gtaaatttat ctagaatggt actattgatg ctggaaaggt gttgaagttg 2940
tccaatattg tgtcaaatca ccaactattt gacatttgtc tttttc 2986

<210> 5
<211> 3185
<212> DNA
<213> Drosophila melanogaster

<400> 5
cggaatttcc tcgctgaagg gcaaggggca gagtcagagt caggggcaga gcggcagacg 60
ctgcccggcc atcgcgggtc ggtgaggagc gagagtggaa gcgggagcag ccacaccatt 120
ccggcgacgg gcaagagtcc gccggtgccg cactcgctgg cggccaagat cagcagctcg 180
gcaagcggca gcaagaactg caatttgctc agcgccagca gcaactcatg ccacaagctg 240
aacgcccacg cccaaggatc ggagcaggat cgggatcttg gatcgggatc aggatcagga 300
ccacccggac acagtcacta cgcggccgcc tcgcccaaaa gctcggtcag cagcaacggt 360
catctgaaca agtactgcct cacggacctc acgcgccgca acgcgagttc aatcgccagc 420
tgagcgcgcc cacggactac acgcaccact cctccagcaa cggatcgcag caggagggct 480
cctcggaggc caacgagggc cacgaaccgg tcggcgagtc caccatcacc gtagccagtg 540
ccggcgtatc gtatccgcat ccgtactcct atccgtatca ttacggcacc accgctcctc 600
ggccacagcg ccggccaatc tcaaggcgtc gctgcagctg cacagctttg ggagccacca 660
tccgtgtcct tatccggcaa ggcccacgtc cacgtcgtgc accaacagct tcaaccggcg 720
ccacattcgc cggcacaagg gcaagctcgg cgatcgactg ctgagcgggg atagtgagga 780
atcggtgcgc tgctcctatt gctcggtgct gaatgcgaac gacaacgacc tgcgcatttc 840
gttcgagaac acctgcaccg attcgctggt aaccgctttc gatgatgaag ccctgctaat 900
atgcgaccaa ggaaccgaaa tggtacactt tgatgacgtg tcgttgtacg gcactccgaa 960
agaggagccc atgcccaaca taccgatcgt gtcggaaaaa gtctctgcga atttcctaaa 1020
aagtcaattg caatcatggt tccagccgac ggacaaccga ctggccatga aactgtttgg 1080

cagccgaaag gcgctggtca aggagcgcat acgtcagaaa acttccgggc actgggtcat 1140
acacccgtgc agttcattca ggttttactg ggacctttgc atgcttttat tattagtagc 1200
aaatcttatt atcctgccag tcgcaatatc attcttcaac gatgatctga gcacacgatg 1260
gattgccttc aactgcctaa gtgatactat ttttttaata gatattgtag tcaattttag 1320
aacaggaatt atgcaacaag acaacgctga acaagtaata ttggatccaa agcttatagc 1380
taaacactat ttaagaactt ggtttttctt cgatttgatt tcgtcgatac cgctagatta 1440
tatattttta attttcaatc aaattatgaa attgcaggat ttctctgatt cttttcaaat 1500
attgcatgcc ggacgcgccc tgccgatcct gcgcctggcc aagctgttat ccctggtgcg 1560
actgctccgc ctttcccgcc tcgtccgcta cgtttcccaa tgggaggagg tctatttcct 1620
caatatggcc tcggtcttca tgaggatctt caatttaatt tgcatgatgc tcctgatcgg 1680
ccattggagc ggttgcttgc agttcttagt gccaatgttg cagggtttc catccaactc 1740
ctgggtctcc atcaacgagt tgcaggaatc gtactggctg gagcagtatt cgtgggcatt 1800
gttcaaggcc atgtcgcaca tgctctgcat aggctacggc agattcccgc cacaatcact 1860
gacagacatg tggctgacga tgctatcgat gatatccggg gccacctgtt acgcattgtt 1920
cctcggtcac gcgaccaatc tcatccagag cttggactcc agccggcgcc agtatcgcga 1980
gaaggtcaaa caggtggagg agtacatggc ctaccgcaag ctgccacgcg acatgcggca 2040
gcgcatcacg gaatatttcg agcatcggta ccagggtaaa ttcttcgatg aagagttgat 2100
acttggcgag ttgagcgaaa aactgcgcga ggatgtcatc aactacaact gcagatccct 2160
cgtggcgtca gtgccttttt ttgctaatgc cgattcgaat ttcgtttccg acgtagttac 2220
caaactgaaa tacgaagttt tccaaccagg tgatattatc ataaaggagg gtacgatcgg 2280
tactaagatg tacttcatac aggagggcgt ggtggacatt gtcatggcca acggcgaggt 2340
tgccacctca ctttcggatg ggtcttattt cggtgagatc tgtctgctga ccaatgcgcg 2400
tcgtgtggcc agcgtgcgag ccgaaaccta ttgcagtcta ttctcgttga gcgtggatca 2460
tttcaattgc gttctggatc agtatccgct gatgcgcaag accatggaga ctgtggccgc 2520
cgagcggtta aacaagatcg gcaagaatcc aaacataatg catcagaagg acgagcagct 2580
gagcaatccg gagtcgaaca cgattacggc tgtggttaat gcactggctg ccgaggcgga 2640
tgactgcaaa gatgatgaca tggatctcag ggagaattta ctgcatgggt cagagtcgag 2700
cattgctgag ccggtgcaga cgatacgtga gggtctcccg aggccacgga gcggggagtt 2760
ccgggccttg ttcgagggta acactccatg acactgagga gcagtgacaa gcggtgccct 2820
cgggcaccgg gcaaccatct gaagcagcag ttcgctggac actcactcac caagtcccac 2880
atccatactc cacacaggac taccactcac acacacacac acactgcgta tataataatt 2940
tagtaaaagg aaccccaaga cgcgataaga gtacactaaa aaaagaatca atttatggta 3000
gacactctat atatgcaatt gcgatttagt agaaaacgta ttaaaaacta aaaacccaaa 3060
aaaagaagat aaaaacaatt acacaaaaaa tgtcctcaat aattattcat aatttcagct 3120
ccgctaactg tgatgacttt aatataagaa tcgaaaaaaa aattaacaaa caaacaaaaa 3180
aaaag 3185

<210> 6
<211> 2922
<212> DNA
<213> Bos taurus

<400> 6
cgggagcccg gagcgcagcc actgagggca gcggcggcgg cgggagcgag gcgcgcagcg 60
agaagcggcg gcgaggaatc ggccgggggc ttcgaggacg ccgaggggcc ccggcggcag 120
tacggcttca tgcagcggca gttcacctcc atgctgcagc ccggggtcaa caaattctcc 180
ctccgcatgt tcgggagcca gaaggcggtg gagaaggagc aggaaagggt taaaactgca 240
ggcttctgga ttatccaccc ttacagtgat ttcaggtttt attgggattt aataatgctt 300
ataatgatgg ttggaaatct ggtcatcata ccagttggaa tcacattctt tacagaacag 360
acaacaacac catggattat tttcaatgtg gcttcagata cagttttcct tttggacttg 420
atcatgaatt tcaggactgg gactgtcaat gaagacagtt ctgaaatcat cctggaccct 480
aaagtgatca agatgaatta tttaaaaagc tggtttgtgg ttgacttcat ctcatcaatc 540
ccagtggatt atatctttct cattgtagaa aaaggaatgg attcggaagt ttacaagaca 600
gccagggcac ttcgcattgt gaggtttaca aaaattctca gtctcttgcg tttattacga 660
ctttcaaggt taattagata catacatcag tgggaagaga ttttccacat gacatatgat 720
cttgccagtg ctgtggtgag aatttttaac ctcattggca tgatgctgct cctgtgccac 780
tgggatggct gtcttcagtt cctggtacca ctgctgcagg acttcccacc agattgctgg 840
gtgtctctaa atgagatggt taatgattct tggggaaagc agtattccta cgcgctcttc 900
aaagcgatga gtcatatgct gtgcattggc tacggagccc aagcccccgt gagcatgtct 960
gacctgtgga tcaccatgct gagcatgatc gtcggggcca cctgctacgc catgtttgtt 1020

```
ggccacgcca cggctctaat tcagtctttg gattcctcaa ggcggcaata tcaagagaag 1080
tataagcaag tggaacaata catgtcattc cataagttac cagctgatat gcgtcagaag 1140
atacatgatt attatgaaca cagataccaa ggcaaaatct ttgatgagga aaatattctc 1200
aatgaactca atgatcctct gagagaggag atagtcaact tcaactgccg aaaactagtg 1260
gctacaatgc ctctttttgc taatgcggat cctaatttcg tgaccgccat gctgagcaag 1320
ttgagatttg aggtgtttca acctggagat tatatcatac gagaaggagg ctgtggtaaa 1380
aaaatgtatt tcattcaaca tggtgttgct ggtgtcatca caaaatccag taaagaaatg 1440
aagctgacag atggctcata ctttggagag atttgcttgc tgaccaaggg acggcgcact 1500
gccagtgttc gagctgatac atattgtcgt ctttactcac tttctgtgga caatttcaat 1560
gaggtcctgg aggaatatcc aatgatgaga agagcctttg agacggttgc cattgaccga 1620
ttagatagga taggtactgt ttattttctt ctttacttac aattcacttt taatctagtg 1680
gttgagtata tatttgcagt cataagtccc aaatgctagt ttacagattg cttattaact 1740
agcatagaaa cagcaattag ctgtagccat atttctagaa gatctgaggc actaacttct 1800
cgtctaagta ttctaggttt gtttattcat ctctgttttt actagcttca cagtctgatt 1860
tcctcagtga taccaaaagg taaaaccaat gattacaaat tctagatggc attaaaatag 1920
wwctnaaaaa tacaatagta tgagtctaca ttacaaacta tattttatna caagtttttt 1980
ttttaanntt aagggtcaac attacattta ttcttatatt aagaattgaa aagaattgtg 2040
cattttactt gtcacagtag aaacgttaat gtttgtaata crrrctcaag cagaaaaagc 2100
cttaatagaa ctgcccacat agatgcttta ttttgcaaac atcaacttat tttaaaatct 2160
ttcctgctct caaattaaaa tattgatata taaggcctta ctagttatac tagtttaaac 2220
gtctgaataa ttgccatgta aaaattagat cagattggct tgctgttaac ttcccaagat 2280
atgctggaac attctgatgt cagaaggtgg tatgcattca ttttccacac ccaaattctc 2340
ctccccgacc agacccttct ctgctccctt tcccagctta actctactag ccttcatagt 2400
tcaatttaaa catcatttcc ctgtagaaac cnatngacct tccactcctc cttaatrrta 2460
tgagcaccct ggatatgttc tnccataccc ctgggatgtt cctccatcac agtacagntt 2520
ttattattta aattgctcta gagatnctaa gctttatgaa tnaagagatc angtctaatt 2580
cactattaca ttcacagtac cwwgtacaca atgaatattg ttgaagagag ttagggaggg 2640
atgaaggaat caatgaactc aaaggagatg gggttgggat cactgaaaag taaacaaaga 2700
ggtacttcaa ctgcttcatt cttattaaag gtaaggactt ttgattgatg ttacanttat 2760
gttagctttt cttctgcact ttancatctt tcttttcctc tatattagta ggacagaaga 2820
ctgcataagg atctagggtt tggttaggac aagtaaaggt agtatttggg cattaccatt 2880
atggacacaa caaggcttcc aggtggataa caataataac gg                    2922
```

<210> 7
<211> 1820
<212> DNA
<213> Bos taurus

<400> 7

```
cggcggacga ggcgggcagc gaggaggcgg gcccggcggg ggagtcgcgc ggcagccagg 60
ccagcttcat gcagcgccag ttcggcgcgc tcctgcagcc gggcgtcaac aagttctcgt 120
tgcggatgtt cggcagtcag aaggccgtgg agcgcgacga ggagcgcgtt aagtcagcgg 180
gggcctggat catccacccct tacagcgact tcaggttcta ctgggacttc accatgctgc 240
tcttcatggt gggaaacctc atcatcatcc ccgtgggcat caccttcttc aaggacgaga 300
ccacggcccc atggattgtg ttcaatgttg tctcggacac attcttcctc atggacctgg 360
tgctgaactt ccgcacgggc attgtgatcg aggacaacac ggagatcatc ctggaccccg 420
agaagatcaa gaagaagtac ctgcgcacgt ggttcgtggt ggacttcgta tcctccatcc 480
ccgtggtaag ctacatcttc ctcatcgtgg agaaaggcat cgactctgag gtctacaaga 540
cggcccgcgc cctgccgatc gagccgttca ccaagatcct cagcctgctg cgcctgctcc 600
gcttgtcgcg cctcatccgc tacatccatc agtgggagga gatcttccac atgacctacg 660
acctggcgag cgccgtcatg cgcatctgca acctcatcag catgatgctg ctcctctgcc 720
actgggatgg ctgcctgcag ttcctggtgc ccatgcttca ggacttccca cgcaactgct 780
gggtctccat caacggcatg gtgaaccact catggagcga gctctactcc ttcgcgctgt 840
tcaaggccat gagccacatg ctgtgcatcg ggtacgggcg gcaggcgcca gaaagcatga 900
cggacatctg gctgaccatg ctgagcatga tcgtgggtgc cacctgctac gccatgttca 960
ttggccacgc caccgccctc atccagtcgc tggactcctc aaggcgccag taccaggaga 1020
agtacaagca agtggagcag tacatgtcct tccacaagct gccagccgac ttccgccaga 1080
agatccacga ctactacgag caccgctacc agggcaagat gttcgacgag gacagcatcc 1140
tcggcgagct caaggcgggc ctgcgggagg agatcgtcaa cttcaactgc cggaagctgg 1200
tggcctccat gccactgttc gccaatgctg accccaactt cgtcacgggc catctgacca 1260
```

agctcaagtt tgaggtcttc cagccaggcg actacatcat ccgtgagggc accattggca 1320
agaagatgta cttcatccaa cacggcgtgg tcagtgtgct taccttgggc aacaaggaga 1380
tgaagttgtc tgatggctcc tactttgggg agatctgcct gctgacgcgg ggccggcgca 1440
cggcgagcgt ccgggccgac acctactgcc gcctctactc gctgagtgtg gacaacttca 1500
atgaggtgct ggaggagtac cccatgatga ggcgggcctt tgagacagtc gccattgacc 1560
gcctggatcg cattggcaag aagaactcga tcctgctaca caaggtgcag cacgacctca 1620
actctggcgt gtttaacaac caggagaacg ccatcatcca ggagattgtc aagtatgacc 1680
gcgagatggt gcagcaggct gagctgggcc agcgtgtcgg cctcttcccg ccaccaccgc 1740
cacctccaca gggcacctca gccattgcca cgctgcagca gccgtggcca tgagcttctg 1800
tccacaagtc gcacgccccc 1820

<210> 8
<211> 101
<212> DNA
<213> Rattus rattus

<400> 8
ctacatcatc cgagagggga ccatcgggaa gaagatgtac ttcatccagc acggggtggt 60
gagcgtgcta accaggggca acaaggagga taagctgtca n 101

<210> 9
<211> 558
<212> DNA
<213> Rattus rattus

<400> 9
tctggtggtg cgtgagggct ccgtgggcag gaagatgtac ttcatccagc atggcgtgct 60
cagtgtgttg gcacggggcg ctcgggacac tcgcctcact gacggatcct actttgggga 120
gatctgcctg ctgactcgag gtcggagaac agccagtgta agggctgaca cctactgtcg 180
cctctactca ctcagcgtgg accacttcaa tgcagtgctt gaggagctcc cgatgatgcg 240
cagggctttt gagactgtgg ccatggaccg gcttcggcgc atcggtgagg cctgtctgcc 300
ctgtctgctc tgggccctgc ctgagcctca tctcattttc atagcaagga acctacccct 360
agtgtttctt ctccacaccc caacctaccc agtaccagca ggctattagc tctgtttctc 420
gctagtctta cccctagaaa gaaatagcca tggagctgtc tccccaaacc ctcattccct 480
gtgtcctctc gggtaccagt acttaacctc accgtttttg ataccacctt ccagtttctg 540
ttgccaagca ttctctcc 558

<210> 10
<211> 2886
<212> DNA
<213> Homo sapiens

<400> 10
gaattcgcgg ccgcgtcgac ggccagcttc atgcagcgcc agttcggcgc gctcctgcag 60
ccgggcgtca acaagttctc gctgcggatg ttcggcagcc agaaggccgt ggagcgcgag 120
caggagcgcg tcaagtcggc gggggcctgg atcatccacc cgtacagcga cttcaggttc 180
tactgggact tcaccatgct gctgttcatg gtgggaaacc tcatcatcat cccagtgggc 240
atcaccttct tcaaggatga gaccactgcc ccgtggatcg tgttcaacgt ggtctcggac 300
accttcttcc tcatggacct ggtgttgaac ttccgcaccg gcattgtgat cgaggacaac 360
acggagatca tcctggaccc cgagaagatc aagaagaagt atctgcgcac gtggttcgtg 420
gtggacttcg tgtcctccat ccccgtggac tacatcttcc ttattgtgga gaagggcatt 480
gactccgagg tctacaagac ggcacgcgcc ctgcgcatcg tgcgcttcac caagatcctc 540
agcctcctgc ggctgctgcg cctctcacgc ctgatccgct acatccatca gtgggaggag 600
atcttccaca tgacctatga cctggccagc gcggtgatga ggatctgcaa tctcatcagc 660
atgatgctgc tgctctgcca ctgggacggc tgcctgcagt tcctggtgcc tatgctgcag 720
gacttcccgc gcaactgctg ggtgtccatc aatggcatgg tgaaccactc gtggagtgaa 780
ctgtactcct tcgcactctt caaggccatg agccacatgc tgtgcatcgg gtacggccgg 840
caggcgcccg agagcatgac ggacatctgg ctgaccatgc tcagcatgat tgtgggtgcc 900
acctcgtacg ccatgttcat cggccacgcc actgccctca tccagtcgct ggactcctcg 960
cggcgccagt accaggagaa gtacaagcag gtggaacagt acatgtcctt ccacaagctg 1020

ccagctgact tccgccagaa gatccacgac tactatgagc accgttacca gggcaagatg 1080
tttgacgagg acagcatcct gggcgagctc aacgggccnn tgcggnagga gatcgtcaac 1140
ttcaactgcc ggaagctggt ggcctccatg ccgctgttcg ccaacgccga ccccaacttc 1200
gtcacggcca tgctgaccaa gctcaagttc gaggtcttcc agccgggtga ctacatcatc 1260
cgcgaaggca ccatcgggaa gaagatgtac ttcatccagc acggcgtggt cagcgtgctc 1320
actaagggca acaaggagat gaagctgtcc gatggctcct acttcgggga gatctgcctg 1380
ctcacccggg gccgccgcac ggcagcgtgc gngctgacac ctactgccgc ctctattcgc 1440
tgagcgtgga caacttcaac gagntgctgg aggagtaccc catgatgcgg cgcgccttcg 1500
agacggtggc catcgaccgc ctggaccgca tcggtgagcg ggccgggggc gtggccgggg 1560
cgggtgccct ggcgggggag gggcgtggcc aaggcatcag gagagtggct tggacagtgg 1620
caggggaag ggcgtggctg tggcatcagg ggcacggttg gggcagagac gtggccaagg 1680
catncaggag tgtggccatg gcagcagggg cgtggctggg gcaggggcag cggctggccg 1740
ctcctaggac ccctttgggt ctagaggctg attttctgac ctattgtcct acttcagcca 1800
gaggcagcct gtttcccaag ggagggaatg cacagggtgt ttgcggttgt gccgaatgct 1860
cggtgagcac ctgctgtgtg ctgggggtgc aggggacaga cccgggggcc cactcagact 1920
cccagggagg cttatggact ggtgatgaaa tcacacacga ctgggctgtg tgccagcagg 1980
gcaggtgggg ccggtgggct tccctgagtt gggaatgcag agtggagacc agggtaaggg 2040
atgccatgtg gaaacgggga ggaagatgtg ttcgtggagt ggacacagca catcccaagg 2100
ccctgaggtg gaaaagaggc ctagagtcca gagagccagg gaggcctgga ggaggttggg 2160
gaagaagggg aggccagaca cacagggccc agtgggcggc agggagagtt tagactaaat 2220
caggagcatc agggagccat ggagggttct aggtgggcgg aggacctggt cagattgtat 2280
ccgccaaggc gggccgtgtc caggagggag acggtgacct ggcctctcag gggggcagtc 2340
tctggggcag ggagggncag agccctgatg actggatgta ggcgccagag agatggcggc 2400
tcatgctgct gttcgtggga atgggaatga agaccatggc tgaaacgcag gacaggtgcg 2460
acggagtggt gtcagggagc tccctggtgt acagtaggaa gctctccaca acttgctcta 2520
tacagtgagt atgcaacccg ttcctgagta tcaggtgctt aggttataac ttctgtatac 2580
agcaggtgct cagcacaggc tgtgtacagg caggtgtttt cggtatgcct gtggcacact 2640
ggaggcagtc attacataat cagcgtatac aggtggtaca catgcatact tggtgcacag 2700
tgatacctgc tccatgtaca cagcaggcat taaatacctg tttactgcca ggcgcggtgn 2760
ntcacgcctg tagtcccagc actttcggag gccaaggtgg gtggatcacg aggtcaggag 2820
attgagacca tcctggctaa catggtgaaa ccccgtctct actaaaaaaa aaaaaaaaaa 2880
aaaaaa 2886

<210> 11
<211> 2029
<212> DNA
<213> Homo sapiens

<400> 11
gcgngccgcg tcgacgtggc ctccatgcca ctgtttgcca atgcggaccc caacttcgtg 60
acgtccatgc tgaccaagct gcgttttgag gtcttccagc ctggggacta catcatccgg 120
gaaggcacca ttggcaagaa gatgtacttc atccagcatg gcgtggtcag cgtgctcacc 180
aagggcaaca aggagaccaa gctggccgac ggctcctact ttggagagat ctgcctgctg 240
acccggggcc ggcgcacagc cagcgtgagg gccgacacct actgccgcct ctactcgctg 300
agcgtggaca acttcaatga ggtgctggag gagtacccca tgatgcgaag ggccttcgag 360
accgtggcgc tggaccgcct ggaccgcatt ggcaagaaga actccatcct cctccacaaa 420
gtccagcacg acctcaactc cggcgtcttc aactaccagg agaatgagat catccagcag 480
attgtgcagc atgaccggga gatggcccac tgcgcgcacc gcgtccaggc tgctgnctct 540
gccaccccaa cccccacgcc cgtnatctgg accccgctga tccaggcacc actgcaggct 600
gccgctgcca ccacttctgt ngccatagcc ctcacccacc acccytcgcn tgnctgytgc 660
natnttnncg scctnccccc anggatctnn gggctggnca amctcggtgc cggnmagang 720
ccaaggcacc tgnaacggct gnagtncctg atcccttctg cgctggtccg cctcgcccgc 780
cagcagcccg tcccaggtgg acacaccgtc ttcatcctcc ttccacatcc aacagctggc 840
tggattctct gcccccgctg gactgagccc actcctgccc tcatccagct cctccccacc 900
ccccggggcc tgtggctccc cctcggctcc cacaccatca gctgcgtagc cgccaccacc 960
atagccgggt ttggccactt ccacaaggcg ctgggtggct ccctgtcctc ctccgactct 1020
cccctgctca ccccgctgca gccaggcgcc cgctccccgc aggctgccca gccatctccc 1080
gcgccacccg gggcccgggg aggcctggga ctcccggagc acttcctgcc acccccaccc 1140
tcatccagat ccccgtcatc tagccccggg cagctgggcc agcctcccgg ggagttgtcc 1200
ctaggtctgg ccactggccc actgagcacg ccagagacac ccccacggca gcctgagccg 1260

ccgtcccttg tggcaggggc ctctggggn ggnttcccst gtaggncttt actccccgag 1320
gaggtntcag cccccstggn ccacagccna gscccccnaa gaaccttccc gagtgccccg 1380
ccccggncnt ctggctccca crgantcnnn cttryycctg ccacctgcat ccagcccccc 1440
accaccccag ntcccccagc gccgggncac acccccgctc acccccggcc gcctcaccca 1500
ggacctcaag ctcatctccg cgtctcagcc agccctgcct caggacgggg cgcagactct 1560
ccgcagagcc tccccgcact cctcagggga gtccatggct gccttcccgc tcttccccag 1620
ggctgggggt ggcagcgggg gcagtgggag cagcgggggc ctcggtcccc ctgggaggcc 1680
ctatggtgcc atccccggcc agcacgtcac tctgcctcgg aagacatcct caggttcttt 1740
gccacccccct ctgtctttgt ttggggcaag agccacctct tctgggggc cccctctgac 1800
tgctggaccc cagagggaac ctggggccag gcctgagcca gtgcgctcca aactgccgtc 1860
caatctatga gctgggccct tccttccctc ttctttcttc ttttctctcc cttccttctt 1920
ccttcaggtt taactgtgat taggagatat accaataaca gtaataatta tttaaaaaac 1980
cancasacac cagaaaaaca aaagacrrnc agaaagtcga cgcggccgc 2029

<210> 12
<211> 2984
<212> DNA
<213> Bos taurus

<400> 12
gggcaccagc cgcgccggag cccggagcgc agccactgag ggcagcggcg gcggcgggag 60
cgaggcgcgc agcgagaagc ggcgcgggcg ggaagcagaa gccgccgccg ccgccgccgc 120
cgccgcgacg ggcagccggg ctcggcggcc gccggatcgg gcccctgccc cctccgcctc 180
gtgtccccgg cgccgggcgg ccggcgagtc tggagcccgc gccgtcgccg gccgcgtccc 240
ccgggcatgg aaggaggcgg caagcccaac tcctcgtcca acagccggga cgatggcaac 300
agcgtcttcc ccaccaaggc gcccgcgacg ggcgcggggc cggccgcggc cgagaagcgc 360
ctgggcaccc cgccgggggg cggcgggacc ggcgcgaagg agcacggcaa ctcagtgtgc 420
ttcaaggtgg acggcggcgg cggcggcggc gaggaatcgg ccgggggctt cgaggacgcc 480
gaggggcccc ggcggcagta cggcttcatg cagcggcagt tcacctccat gctgcagccc 540
ggggtcaaca aattctccct ccgcatgttc gggagccaga aggcggtgga gaaggagcag 600
gaaagggtta aaactgcagg cttctggatt atccaccctt acagtgattt caggttttat 660
tgggatttaa taatgcttat aatgatggtt ggaaatctgg tcatcatacc agttggaatc 720
acattcttta cagaacagac aacaacacca tggattattt tcaatgtggc ttcagataca 780
gttttccttt tggacttgat catgaatttc aggactggga ctgtcaatga agacagttct 840
gaaatcatcc tggaccctaa agtgatcaag atgaattatt taaaaagctg gtttgtggtt 900
gacttcatct catcaatccc agtggattat atctttctca ttgtagaaaa aggaatggat 960
tcggaagttt acaagacagc cagggcactt cgcattgtga ggtttacaaa aattctcagt 1020
ctcttgcgtt tattacgact ttcaaggtta attagataca tacatcagtg ggaagagatt 1080
ttccacatga catatgatct tgccagtgct gtggtgagaa tttttaacct cattggcatg 1140
atgctgctcc tgtgccactg ggatggctgt cttcagttcc tggtaccact gctgcaggac 1200
ttcccaccag attgctgggt gtctctaaat gagatggtta atgattcttg gggaaagcag 1260
tattcctacg cgctcttcaa agcgatgagt catatgctgt gcattggcta cggagcccaa 1320
gcccccgtga gcatgtctga cctgtggatc accatgctga gcatgatcgt cggggccacc 1380
tgctacgcca tgtttgttgg ccacgccacg gctctaattc agtctttgga ttcctcaagg 1440
cggcaatatc aagagaagta taagcaagtg gaacaataca tgtcattcca taagttacca 1500
gctgatatgc gtcagaagat acatgattat tatgaacaca gataccaagg caaaatcttt 1560
gatgaggaaa atattctcaa tgaactcaat gatcctctga gagaggagat agtcaacttc 1620
aactgccgaa aactagtggc tacaatgcct ctttttgcta atgcggatcc taatttcgtg 1680
accgccatgc tgagcaagtt gagatttgag gtgtttcaac ctggagatta tatcatacga 1740
gaaggagctg tgggtaaaaa aatgtatttc attcaacatg gtgttgctgg tgtcatcaca 1800
aaatccagta aagaaatgaa gctgacagat ggctcatact ttggagagat ttgcttgctg 1860
accaagggac ggcgcactgc cagtgttcga gctgatacat attgtcgtct ttactcactt 1920
tctgtggaca atttcaatga ggtcctggag gaatatccaa tgatgagaag agcctttgag 1980
acggttgcca ttgaccgatt agataggata gggaagaaaa attcaattct cctgcaaaag 2040
ttccagaagg atctgaacac gggtgttttc aacaatcagg agaacgagat cctgaagcag 2100
attgtgaaac acgacaggga aatggtgcag gcaatccctc ccctcaatta ccctcaaatg 2160
acagccctga attccacctc ttcaactact accccgacct ctcgcctgag gacacagtca 2220
ccgccagtgt acacagccac cagtctgtct catagcaacc tgcactcccc cagccccagc 2280
acccagaccc cccagccgtc agccatcctc tcgccctgct cctacaccac cgctgtctgc 2340
agccctcctg tacagagccc gctagccact cgaactttcc actatgcctc ccccacggct 2400

tcccagttgt ccctcattca gcagcagcag gttcagcagc caccgcagcc ccagcagcca 2460
ccccaacctc cacagacccc cggcagctcc acaccgaaaa acgaagtgca caagagcacg 2520
caggcgcttc acaacaccag cctgacccga gaagtcaggc ccctctcggc ctcgcagccc 2580
tcgctgcccc acgaggtctc caccctgatc tccagaccgc atcccactgt gggcgagtcc 2640
ctggcctcca tccctcaacc cgtgaccacg gtccacggct cgggcctgca ggcagggggc 2700
aggggcaccg tcccccagcg agtcaccctg ttccgacaga tgtcatcggg agccatcccc 2760
cccaatcgag gagtcccccc ggccccccct ccaccagcag ccgctcatcc gagggaggcg 2820
ccctcagtct taactacaga ctcagaggca gaaaagccac gatttgcttc aaatttatga 2880
tcctgctgat tgtaaagcag aaagaaatac tctaacgtaa ctgaggacgc ttctcagatt 2940
tgattttatt ctatctcctg atagatcctc tagcctacta tgaa 2984

<210> 13
<211> 794
<212> DNA
<213> Rattus rattus

<400> 13
tgcctgcagt tcctggtgcc catgctgcaa gacttcccca gcgactgctg gtgtccatca 60
acaacatggt gaaccactcg tggagcgaac tctattcgtt cgcgctcttc aaggccatga 120
gccacatgct ctgtattggc tacgggcggc aggctcccga gagcatgacg gacatctggc 180
tcaccatgct cagcatgatc gtgggcgcca cctgctacgc tatgttcatt gggcacgcca 240
cggcgcttat ccagtccctg gactcgtcac ggcgccagta ccaggagaag tacaagcaag 300
tggagcagta catgtccttc cacaaactgc cggctgactt ccgccagaag atccacgatt 360
actatgaaca ccggtaccag gggaagatgt ttgacgagga cagcatcctg ggggaactca 420
acggcccact gcgtgaggag attgtgaact tcaactgccg gaagctggtg gcttccatgc 480
cgttgtttgc caacgcagac cccaacttcg tcaccgccat gctgacaaag ctcaaatttg 540
aggtcttcca gcctggagac tacatcatcc gagaggggac catcgggaag aagatgtact 600
tcatccagca cggggtggtg agcgtgctca ccaagggcaa caaggagatg aagctgtcag 660
atggctccta ttttggggag atctgcctgc tcacgagggg ccggcgcaca gccagtgtgc 720
gggctgacac ctactgtcgc ctctactcac tgagcgtgga caacttcaac gaggtgctgg 780
aggagtaccc catg 794

<210> 14
<211> 649
<212> DNA
<213> Rattus rattus

<400> 14
tccagcatgg gctgctcagt gtgttggcac ggggcgctcg ggacactcgc ctcactgacg 60
gatcctactt tggggagatc tgcttgctga ctcgaggtcg gagaacagcc agtgtaaggg 120
ctgacaccta ctgtcgcctc tactcactca gcgtggacca cttcaatgca gtgcttgagg 180
agctcccgat gatgcgcagg gcttttgaga ctgtggccat ggaccggctt cggcgcatcg 240
gcaaaaagaa ttcgatattg cagcggaaac gctctgagcc gagtccaggc agcagcagtc 300
gtggcgtcat ggagcagcat ttggtacaac acgacagaga catggctcgt ggtattcggg 360
gtctggctcc gggcacagga gcccgcctca gtggaaagcc agttctgtgg gaaccactgg 420
tacacgcacc tcttcaggca gctgctgtga cctccaacgt ggccatagcc ttgactcatc 480
agcgaggccc tctgcccctc tcccctgatt ctccagccac cctcctggct cgatctgcta 540
gacgctcagc aggctcccca gcctccccac tggtgcctgt tcgagcaggt cctctgctgg 600
cccggggacc ctgggcgtcc acttctcatc ttcctgccca cgggccctc 649

<210> 15
<211> 4751
<212> DNA
<213> Homo sapiens

<400> 15
tcgacaaaaa tgccagggaa aggcgagccc agagcttggt gatggagaaa ttgggaagcc 60
acccccccacc cttcaatctt aggatgggga attcgcaact gaagccggag cttcagactt 120
ggggcgcact cccagcttag cccaggaaag agatttaagg gcgcagcagt gtggatacct 180
ctcaccccgg ccccgaaggt ctagcgaggg tctaacctgg gccccttgcc aggcccgccc 240

```
cccgcccctt tccagccccc ggcccgtgcg ccgctgcccc tttaagaagc ccaggtaggc 300
aggcccggct gctggagccg ctcctatggc aacccgcgag ctgcggcggc ttcatgaata 360
ttccggggcg cgggagcccg agcgctgccg gagggcgctt cgggggaggc ggccgctgat 420
gtaagcccgg cgggtcgctg ggctccgctc ggttgcggcg ggagccccgg gacgggccgg 480
acgggccggg gcagaggagg cgaggcgagc tcgcgggtgg ccagccacaa agcccgggcg 540
gcgagacaga cggacagcca gccctcccgc gggacgcacg cccgggaccc gcgcgggccg 600
tgcgctctgc actccggagc ggttccctga gcgccgcggc cgcagagcct ctccggccgg 660
cgcccattgt tccccgcggg ggcggggcgc ctggagccgg gcggcgcgcc gcccctgaac 720
gccagaggga gggagggagg caagaaggga gcgcggggtc cccgcgccca gccgggcccg 780
ggaggaggtg tagcgcggcg agcccgggga ctcggagcgg gactaggatc ctccccgcgg 840
cgcgcagcct gcccaagcat gggcgcctga ggctgccccc acgccggcgg caaaggacgc 900
gtccccacgg gcggactgac cggcgggcgg acctggagcc cgtccgcggc gccgcgctcc 960
tgcccccggc ccggtccgac cccggcccct ggcgccatgg acaagctgcc gccgtccatg 1020
cgcaagcggc tctacagcct cccgcagcag gtgggggcca aggcgtggat catggacgag 1080
gaagaggacg ccgaggagga gggggccggg ggccgccaag accccagccg caggagcatc 1140
cggctgcggc cactgccctc gccctccccc tcggcggccg cgggtggcac ggagtcccgg 1200
agctcggccc tcggggcagc ggacagcgaa gggccggccc gcggcgcggg caagtccagc 1260
acgaacggcg actgcaggcg cttccgcggg agcctggcct cgctgggcag ccggggcggc 1320
ggcacgggcg gcacggggag cggcagcagt cacggacacc tgcatgactc cgcggaggag 1380
cggcggctca tcgccgaggg cgacgcgtcc cccggcgagg acaggacgcc cccaggcctg 1440
gcggccgagc ccgagcgccc cggcgcctcg gcgcagcccg cagcctcgcc gccgccgccc 1500
cagcagccac cgcagccggc ctccgcctcc tgcgagcagc cctcggtgga caccgctatc 1560
aaagtggagg gaggcgcggc tgccggcgac cagatcctcc cggaggccga ggtgcgcctg 1620
ggccaggccg gcttcatgca gcgccagttc ggggccatgc tccaacccgg ggtcaacaaa 1680
ttctccctaa ggatgttcgg cagccagaaa gccgtggagc gcgaacagga gagggtcaag 1740
tcggccggat tttggattat ccacccctac agtgacttca gattttactg ggacctgacc 1800
atgctgctgc tgatggtggg aaacctgatt atcattcctg tgggcatcac cttcttcaag 1860
gatgagaaca ccacaccctg gattgtcttc aatgtggtgt cagacacatt cttcctcatc 1920
gacttggtcc tcaacttccg cacagggatc gtggtggagg acaacacaga gatcatcctg 1980
gacccgcagc ggattaaaat gaagtacctg aaaagctggt tcatggtaga tttcatttcc 2040
tccatccccg tggactacat cttcctcatt gtggagacac gcatcgactc ggaggtctac 2100
aagactgccc gggccctgcg cattgtccgc ttcacgaaga tcctcagcct cttacgcctg 2160
ttacgcctct cccgcctcat tcgatatatt caccagtggg aagagatctt ccacatgacc 2220
tacgacctgg ccagcgccgt ggtgcgcatc gtgaacctca tcggcatgat gctcctgctc 2280
tgccactggg acggctgcct gcagttcctg gtacccatgc tacaggactt ccctgacgac 2340
tgctgggtgt ccatcaacaa catggtgaac aactcctggg ggaagcagta ctcctacgcg 2400
ctcttcaagg ccatgagcca catgctgtgc atcggctacg ggcggcaggc gcccgtgggc 2460
atgtccgacg tctggctcac catgctcagc atgatcgtgg gtgccacctg ctacgccatg 2520
ttcattggcc acgccactgc cctcatccag tccctggact cctcccggcg ccagtaccag 2580
gaaaagtaca agcaggtgga gcagtacatg tcctttcaca agctcccgcc cgacacccgg 2640
cagcgcatcc acgactacta cgagcaccgc taccagggca agatgttcga cgaggagagc 2700
atcctgggcg agctaagcga gcccctgcgg gaggagatca tcaactttaa ctgtcggaag 2760
ctggtggcct ccatgccact gtttgccaat gcggacccca acttcgtgac gtccatgctg 2820
accaagctgc gtttcgaggt cttccagcct ggggactaca tcatccggga aggcaccatt 2880
ggcaagaaga tgtacttcat ccagcatggc gtggtcagcg tgctcaccaa gggcaacaag 2940
gagaccaagc tggccgacgg ctcctacttt ggagagatct gcctgctgac ccggggccgg 3000
cgcacagcca gcgtgagggc cgacacctac tgccgcctct actcgctgag cgtggacaac 3060
ttcaatgagg tgctggagga gtaccccatg atgcgaaggg ccttcgagac cgtggcgctg 3120
gaccgcctgg accgcattgg caagaagaac tccatcctcc tccacaaagt ccagcacgac 3180
ctcaactccg gcgtcttcaa ctaccaggag aatgagatca tccagcagat tgtgcagcat 3240
gaccgggaga tggcccactg cgcgcaccgc gtccaggctg ctgcctctgc caccccaacc 3300
cccacgcccg tcatctggac cccgctgatc caggcaccac tgcaggctgc cgctgccacc 3360
acttctgtgg ccatagccct cacccaccac cctcgcctgc ctgctgccat cttccgccct 3420
cccccaggat ctgggctggg caacctcggt gccgggcaga cgccaaggca cctgaaacgg 3480
ctgcagtccc tgatcccttc tgcgctgggc tccgcctcgc ccgccagcag cccgtcccag 3540
gtggacacac catcttcatc ctccttccac atccaacagc tggctggatt ctctgccccc 3600
gctggactga gcccactcct gccctcatcc agctcctccc cacccccggg ggcctgtggc 3660
tccccctcgg ctcccacacc atcagctggc gtagccgcca ccaccatagc cgggtttggc 3720
cacttccaca aggcgctggg tggctccctg tcctcctccg actctcccct gctcaccccg 3780
ctgcagccag gcgcccgctc cccgcaggct gcccagccat ctcccgcgcc acccggggcc 3840
```

cggggaggcc tgggactccc ggagcacttc ctgccacccc caccctcatc cagatccccg 3900
tcatctagcc ccgggcagct gggccagcct cccggggagt tgtccctagg tctggccact 3960
ggcccactga gcacgccaga gacaccccca cggcagcctg agccgccgtc ccttgtggca 4020
ggggcctctg ggggggcttc ccctgtaggc tttactcccc gaggaggtct cagccccccct 4080
ggccacagcc caggcccccc aagaaccttc ccgagtgccc cgcccccgggc ctctggctcc 4140
cacggatcct tgctcctgcc acctgcatcc agccccccac caccccaggt cccccagcgc 4200
cggggcacac ccccgctcac ccccggccgc ctcacccagg acctcaagct catctccgcg 4260
tctcagccag ccctgcctca ggacggggcg cagactctcc gcagagcctc cccgcactcc 4320
tcaggggagt ccatggctgc cttcccgctc ttccccaggg ctgggggtgg cagcgggggc 4380
agtgggagca gcgggggcct cggtccccct gggaggccct atggtgccat ccccggccag 4440
cacgtcactc tgcctcggaa gacatcctca ggttctttgc cacccccctct gtctttgttt 4500
ggggcaagag ccacctcttc tggggggccc cctctgactg ctggacccca gagggaacct 4560
ggggccaggc ctgagccagt gcgctccaaa ctgccgtcca atctatgagc tgggcccttc 4620
cttccctctt ctttcttctt ttctctccct tccttcttcc ttcaggttta actgtgatta 4680
ggagatatac caataacagt aataattatt taaaaaacca cacacaccag aaaaacaaaa 4740
gacagcagaa a 4751

<210> 16
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Degenerated Primer

<400> 16
ctgactgcag argtnttyca rccnggnga 29

<210> 17
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Degenerated Primer

<400> 17
atcggaattc nccraartan ganccrtc 28

<210> 18
<211> 767
<212> PRT
<213> Strongylocentrotus purpuratus

<400> 18
Met Asp Asn Lys Glu Thr Asn Gly Glu Leu Glu Gln Ser Asp Glu Ala
1 5 10 15

Asp Pro Ser Gly Gln Asn Leu Asp Asp Gly Glu Thr Asp Ser Lys Gln
20 25 30

Glu Glu Asn Leu Ile Asn Val Ser Pro Pro Lys Thr Pro Pro Gly Pro
35 40 45

Pro Pro Pro Leu Lys Asn Gly Gly Arg Gly Gln Lys Pro Pro Lys Ile
50 55 60

Pro Ile Cys His Gln Asn Gly Lys Leu Pro Lys Glu Val Glu Trp Thr
65 70 75 80

65 70 75 80

Glu Asp Arg Gly Glu Asp Arg Lys Asp Ser Leu Thr Leu Gln Ser Lys
85 90 95

Leu Asp His Gly Ala Tyr Thr Asp Glu Lys Gln Asp Leu Leu Thr Tyr
100 105 110

Leu Asp Arg His Gly Ile Asn Ser Pro Val Lys Leu Thr Pro Asp Glu
115 120 125

Thr Gly Gly Ser Ser Ala Leu Asp Ile Leu Gly Ile Ile Glu Glu Arg
130 135 140

Asp Thr Gly Ala Leu Gly Ser Asp Pro Ser Ser Thr Met Gln Ala Met
145 150 155 160

Ala Lys Pro Val Gly Phe Leu Gln Arg Gln Leu Trp Thr Val Leu Gln
165 170 175

Pro Ser Asp Asn Arg Leu Ser Met Lys Leu Phe Gly Ser Lys Lys Gly
180 185 190

Leu Gln Lys Glu Lys Tyr Arg Leu Arg Lys Ala Gly Val Leu Ile Ile
195 200 205

His Pro Cys Ser His Phe Arg Phe Tyr Trp Asp Leu Leu Met Leu Cys
210 215 220

Leu Ile Met Ala Asn Val Ile Leu Leu Pro Val Val Ile Thr Phe Phe
225 230 235 240

His Asn Lys Asp Met Ser Thr Gly Trp Leu Ile Phe Asn Cys Phe Ser
245 250 255

Asp Thr Phe Phe Ile Leu Asp Leu Ile Cys Asn Phe Arg Thr Gly Ile
260 265 270

Met Asn Pro Lys Ser Ala Glu Gln Val Ile Leu Asn Pro Arg Gln Ile
275 280 285

Ala Tyr His Tyr Leu Arg Ser Trp Phe Ile Ile Asp Leu Val Ser Ser
290 295 300

Ile Pro Met Asp Tyr Ile Phe Leu Leu Ala Gly Gly Gln Asn Arg His
305 310 315 320

Phe Leu Glu Val Ser Arg Ala Leu Lys Ile Leu Arg Phe Ala Lys Leu
325 330 335

Leu Ser Leu Leu Arg Leu Leu Arg Leu Ser Arg Leu Met Arg Phe Val
340 345 350

Ser Gln Trp Glu Gln Ala Phe Asn Val Ala Asn Ala Val Ile Arg Ile
355 360 365

Cys Asn Leu Val Cys Met Met Leu Leu Ile Gly His Trp Asn Gly Cys
370 375 380

Leu Gln Tyr Leu Val Pro Met Leu Gln Glu Tyr Pro Asp Gln Ser Trp

```
385                 390                 395                 400

Val Ala Ile Asn Gly Leu Glu His Ala His Trp Trp Glu Gln Tyr Thr
                405                 410                 415

Trp Ala Leu Phe Lys Ala Leu Ser His Met Leu Cys Ile Gly Tyr Gly
            420                 425                 430

Lys Phe Pro Pro Gln Ser Ile Thr Asp Val Trp Leu Thr Ile Val Ser
        435                 440                 445

Met Val Ser Gly Ala Thr Cys Phe Ala Leu Phe Ile Gly His Ala Thr
    450                 455                 460

Asn Leu Ile Gln Ser Met Asp Ser Ser Ser Arg Gln Tyr Arg Glu Lys
465                 470                 475                 480

Leu Lys Gln Val Glu Glu Tyr Met Gln Tyr Arg Lys Leu Pro Ser His
                485                 490                 495

Leu Arg Asn Lys Ile Leu Asp Tyr Tyr Glu Tyr Arg Tyr Arg Gly Lys
            500                 505                 510

Met Phe Asp Glu Arg His Ile Phe Arg Glu Val Ser Glu Ser Ile Arg
        515                 520                 525

Gln Asp Val Ala Asn Tyr Asn Cys Arg Asp Leu Val Ala Ser Val Pro
    530                 535                 540

Phe Phe Val Gly Ala Asp Ser Asn Phe Val Thr Arg Val Val Thr Leu
545                 550                 555                 560

Leu Glu Phe Glu Val Phe Gln Pro Ala Asp Tyr Val Ile Gln Glu Gly
                565                 570                 575

Thr Phe Gly Asp Arg Met Phe Phe Ile Gln Gln Gly Ile Val Asp Ile
            580                 585                 590

Ile Met Ser Asp Gly Val Ile Ala Thr Ser Leu Ser Asp Gly Ser Tyr
        595                 600                 605

Phe Gly Glu Ile Cys Leu Leu Thr Arg Glu Arg Arg Val Ala Ser Val
    610                 615                 620

Lys Cys Glu Thr Tyr Cys Thr Leu Phe Ser Leu Ser Val Gln His Phe
625                 630                 635                 640

Asn Gln Val Leu Asp Glu Phe Pro Ala Met Arg Lys Thr Met Glu Glu
                645                 650                 655

Ile Ala Val Arg Arg Leu Thr Arg Ile Gly Lys Glu Ser Ser Lys Leu
            660                 665                 670

Lys Ser Arg Leu Glu Ser Pro Thr Ile Arg Asp Thr Ala Pro Leu Phe
        675                 680                 685

Pro Ile Pro Pro Asp Thr Pro Ser Phe Val Thr Asp Ile Glu Lys Asn
    690                 695                 700

Arg Phe Phe Gly Asp Asp Thr Asp Asp Val His Ile Arg Thr Arg Val
```

705 710 715 720

Asp Val Glu Arg Gly Ser His Glu Asn Val Ile Ala Ile Met Asp Gly
725 730 735

Ser Leu Ser Asp Leu Arg Met Glu Asn Glu Ile Gln Ala Arg Lys Ser
740 745 750

Ser Ser Gly Lys Arg Arg Lys Phe Gln Gln Gln Thr Thr Glu Leu
755 760 765